var docs;if (!docs) docs =[]; docs["107"]={"10700":"<p><b>Title</b> Zolpidem / Itraconazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Itraconazole may increase the serum concentration of Zolpidem. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased zolpidem effects/toxicities if combined with itraconazole.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 10 healthy volunteers, itraconazole (200 mg daily x 4 days) increased the zolpidem (10 mg single dose) AUC 34%.<sup>1</sup> In a separate study of 10 healthy volunteers, a lower dose of itraconaozle (100 mg twice daily x 4 doses) increased the zolpidem (5 mg single dose) AUC and maximum serum concentration 32% and 26%, respectively, but these changes did not reach statistical significance.<sup>2</sup> No pharmacodynamic effects were identified in either study.<br><br>Zolpidem prescribing information states that concomitant use of strong CYP3A4 inhibitors (ie, itraconazole) may increase zolpidem exposure and effects.<sup>3</sup> Monitor for increased zolpidem toxicities and consider using a lower zolpidem dose if these agents are combined.<sup>3</sup><br><br>The mechanism of this interaction is likely due to itraconazole-mediated inhibition of CYP3A4, an enzyme at least partially responsible for zolpidem metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Luurila H, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. <i>Eur J Clin Pharmacol</i>. 1998;54(2):163-166. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9626922\">[PubMed 9626922]</a></p>\n<p>2. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. <i>Clin Pharmacol Ther</i>. 1998;64(6):661-671. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9871431\">[PubMed 9871431]</a></p>\n<p>3. Ambien (zolpidem) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; August 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10701":"<p><b>Title</b> Zolpidem / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of Zolpidem. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 10 healthy volunteers, fluconazole (100 mg twice daily x 4 doses) increased the zolpidem (5 mg single dose) AUC and maximum serum concentration 31% and 17%, respectively, but these changes did not reach statistical significance.<sup>1</sup><br><br>The mechanism of this potential interaction has not been fully investigated, but fluconazole-mediated inhibition of CYP3A4, an enzyme responsible for zolpidem metabolism, may play a role.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. <i>Clin Pharmacol Ther</i>. 1998;64(6):661-671. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9871431\">[PubMed 9871431]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10702":"<p><b>Title</b> Zolpidem / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zolpidem. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased zolpidem effects/toxicities when combined with strong CYP3A4 inhibitors. Consider using a lower starting dose of zolpidem.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In several pharmacokinetic studies, various strong CYP3A4 inhibitors (ie, ketoconazole, voriconazole, itraconazole, ritonavir) increased the AUC, maximum serum concentration, and half-life of zolpidem 31% to 67%, 22% to 35%, and 20% to 30%, respectively.<sup>1,2,3,4</sup> Pharmacodynamic changes coinciding with increased serum concentrations were only reported when zolpidem was combined with ketoconazole.<sup>1</sup><br> <br>In contrast, zolpidem pharmacokinetic parameters were unchanged when zolpidem was combined with clarithromycin and the combination antiviral regimen ombitasvir/paritaprevir/ritonavir/dasabuvir.<sup>5,6</sup><br><br>Zolpidem prescribing information states that the combined use of zolpidem and strong CYP3A4 inhibitors may increase the effects of zolpidem.<sup>7</sup> Use of a lower starting dose of zolpidem should be considered.<sup>7</sup><br><br>The mechanism of this interaction is likely due to inhibition of CYP3A4 isoenzymes, an enzyme responsible for zolpidem metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. <i>Clin Pharmacol Ther</i>. 1998;64(6):661-671. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9871431\">[PubMed 9871431]</a></p>\n<p>2. Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects. <i>Br J Clin Pharmacol</i>. 2007;63(1):116-120. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16822278\">[PubMed 16822278]</a></p>\n<p>3. Luurila H, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. <i>Eur J Clin Pharmacol</i>. 1998;54(2):163-166. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9626922\">[PubMed 9626922]</a></p>\n<p>4. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Differential impairment of triazolam and zolpidem clearance by ritonavir. <i>J Acquir Immune Defic Syndr</i>. 2000;24(2):129-136. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10935688\">[PubMed 10935688]</a></p>\n<p>5. Farkas D, Volak LP, Harmatz JS, von Moltke LL, Court MH, Greenblatt DJ. Short-term clarithromycin administration impairs clearance and enhances pharmacodyamic effects of trazodone but not of zolpidem. <i>Clin Pharmacol Ther</i>. 2009;85(6):644-650. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19242403\">[PubMed 19242403]</a></p>\n<p>6. Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. <i>J Hepatol</i>. 2015;63(1):20-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25646891\">[PubMed 25646891]</a></p>\n<p>7. Ambien (zolpidem) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; August 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10703":"<p><b>Title</b> Dronabinol / Disulfiram</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: Use of the dronabinol oral solution within 14 days of using disulfiram is contraindicated. This is specific to the oral solution and does not apply to the dronabinol capsules.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Disulfiram may enhance the adverse/toxic effect of Dronabinol. Specifically, disulfiram may produce severe intolerance to the alcohol contained in the dronabinol oral solution. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of the dronabinol oral solution within 14 days of using disulfiram is contraindicated. Discontinue disulfiram at least 14 days prior to initiating dronabinol oral solution, and do not administer disulfiram within 7 days of stopping dronabinol oral solution. This specific contraindication is specific to the oral solution and does not apply to the dronabinol capsules.</p> \n<p><b>Discussion</b> The dronabinol oral solution contains 50% (w/w) alcohol and 5.5% (w/w) propylene glycol, both of which may interact with disulfiram to produce effects such as significant nausea and vomiting, abdominal pain, headache, and flushing.<sup>1</sup> As a result, concurrent use of the dronabinol oral solution within 14 days of disulfiram is contraindicated. The dronabinol capsules are not expected to share this specific interaction.<sup>2</sup><br><br>U.S. prescribing information for dronabinol also summarizes a published case report in which a 28-year-old man reproducibly experienced hypomanic episodes after smoking marijuana during treatment with disulfiram.<sup>2,3</sup> Another very brief published case report describes similar symptoms developing in a 36-year-old man who smoked cannabis during disulfiram treatment.<sup>4</sup> It is not presently clear whether the symptoms described in these case reports may have been caused by an interaction between disulfiram and cannabis. There is no known mechanism by which disulfiram would be expected to increase the likelihood of hypomania following cannabis use.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Syndros (dronabinol) oral solution [prescribing information]. Chandler, AZ: Insys Therapeutics, Inc.; July 2016.</p>\n<p>2. Marinol (dronabinol) capsules [prescribing information]. Marietta, GA: Unimed Pharmaceuticals, Inc.; July 2006.</p>\n<p>3. Lacoursiere RB, Swatek R. Adverse interaction between disulfiram and marijuana: a case report. <i>Am J Psychiatry</i>. 1983;140(2):243-244. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6295192\">[PubMed 6295192]</a></p>\n<p>4. Mackie J, Clark D. Cannabis toxic psychosis while on disulfiram. <i>Br J Psychiatry</i>. 1994;164(3):421. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8199803\">[PubMed 8199803]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10704":"<p><b>Title</b> Warfarin / Dronabinol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dronabinol may increase the serum concentration of Warfarin. Specifically, dronabinol may displace warfarin from its protein-binding sites, leading to an increased concentration of active, unbound drug. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of increased warfarin effects (eg, bleeding, bruising, increased INR) with concurrent use of dronabinol, and particularly when starting or increasing the dose of dronabinol.</p> \n<p><b>Discussion</b> Dronabinol and its metabolites are approximately 97% bound to plasma proteins, suggesting dronabinol and its metabolites may displace other drugs from their protein binding sites, possibly resulting in a temporary increase in the effects of the displaced drug.<sup>1,2</sup> The labeling for the dronabinol oral solution includes a warning that caution is warranted when using highly-bound drugs that have a narrow therapeutic index, such as warfarin, cyclosporine, or amphotericin B, particularly when starting dronabinol or increasing the dronabinol dose.<sup>1</sup> The precise risk for or clinical significance of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Syndros (dronabinol) oral solution [prescribing information]. Chandler, AZ: Insys Therapeutics, Inc.; July 2016.</p>\n<p>2. Marinol (dronabinol) capsules [prescribing information]. Marietta, GA: Unimed Pharmaceuticals, Inc.; July 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10705":"<p><b>Title</b> CycloSPORINE (Systemic) / Dronabinol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dronabinol may increase the serum concentration of CycloSPORINE (Systemic). Specifically, dronabinol may displace cyclosporine from its protein-binding sites, leading to an increased concentration of active, unbound drug. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of increased cyclosporine toxicity with concurrent use of dronabinol, and particularly when starting or increasing the dose of dronabinol.</p> \n<p><b>Discussion</b> Dronabinol and its metabolites are approximately 97% bound to plasma proteins, suggesting dronabinol and its metabolites may displace other drugs from their protein binding sites, possibly resulting in a temporary increase in the effects of the displaced drug.<sup>1,2</sup> The labeling for the dronabinol oral solution includes a warning that caution is warranted when using highly-bound drugs that have a narrow therapeutic index, such as warfarin, cyclosporine, or amphotericin B, particularly when starting dronabinol or increasing the dronabinol dose.<sup>1</sup> The precise risk for or clinical significance of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Syndros (dronabinol) oral solution [prescribing information]. Chandler, AZ: Insys Therapeutics, Inc.; July 2016.</p>\n<p>2. Marinol (dronabinol) capsules [prescribing information]. Marietta, GA: Unimed Pharmaceuticals, Inc.; July 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10706":"<p><b>Title</b> Amphotericin B / Dronabinol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dronabinol may increase the serum concentration of Amphotericin B. Specifically, dronabinol may displace amphotericin B from its protein-binding sites, leading to an increased concentration of active, unbound drug. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of increased amphotericin B toxicity with concurrent use of dronabinol, and particularly when starting or increasing the dose of dronabinol.</p>\n<div>\n <p><b>Amphotericin B Interacting Members</b> Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex</p>\n</div> \n<p><b>Discussion</b> Dronabinol and its metabolites are approximately 97% bound to plasma proteins, suggesting dronabinol and its metabolites may displace other drugs from their protein binding sites, possibly resulting in a temporary increase in the effects of the displaced drug.<sup>1,2</sup> The labeling for the dronabinol oral solution includes a warning that caution is warranted when using highly-bound drugs that have a narrow therapeutic index, such as warfarin, cyclosporine, or amphotericin B, particularly when starting dronabinol or increasing the dronabinol dose.<sup>1</sup> The precise risk for or clinical significance of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Syndros (dronabinol) oral solution [prescribing information]. Chandler, AZ: Insys Therapeutics, Inc.; July 2016.</p>\n<p>2. Marinol (dronabinol) capsules [prescribing information]. Marietta, GA: Unimed Pharmaceuticals, Inc.; July 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10707":"<p><b>Title</b> Dronabinol / MetroNIDAZOLE (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: Use of the dronabinol oral solution within 14 days of using metronidazole is contraindicated. This is specific to the oral solution and does not apply to the dronabinol capsules.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Dronabinol. Specifically, metronidazole may produce severe intolerance to the alcohol contained in the dronabinol oral solution. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of the dronabinol oral solution within 14 days of using metronidazole is contraindicated. Discontinue metronidazole at least 14 days prior to initiating dronabinol oral solution, and do not administer metronidazole within 7 days of stopping dronabinol oral solution. This specific contraindication is specific to the oral solution and does not apply to the dronabinol capsules.</p> \n<p><b>Discussion</b> The dronabinol oral solution contains 50% (w/w) alcohol and 5.5% (w/w) propylene glycol, both of which may interact with metronidazole, which has been reported to have a potential to produce a disulfiram-like reaction when combined with alcohol, to produce effects such as significant nausea and vomiting, abdominal pain, headache, and flushing.<sup>1</sup> As a result, concurrent use of the dronabinol oral solution within 14 days of metronidazole is contraindicated. The dronabinol capsules are not expected to share this specific interaction.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Syndros (dronabinol) oral solution [prescribing information]. Chandler, AZ: Insys Therapeutics, Inc.; July 2016.</p>\n<p>2. Marinol (dronabinol) capsules [prescribing information]. Marietta, GA: Unimed Pharmaceuticals, Inc.; July 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10708":"<p><b>Title</b> AmLODIPine / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of AmLODIPine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for evidence of increased amlodipine effects or toxicity when used together with a strong CYP3A4 inhibitor. Amlodipine dose reductions may be needed.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Pharmacokinetic studies have reported 1.9- to 2.8-fold higher amlodipine AUCs with concurrent use of the strong CYP3A4 inhibitors indinavir/ritonavir (800 mg/100 mg every 12 hours) and telaprevir (750 mg every 8 hours) in studies of healthy volunteers.<sup>1,2</sup> No serious adverse effects were noted in these studies, but these studies involved only short-term coadministration (single dose to 7 days of overlap).<br><br>Concurrent use of the strong CYP3A4 inhibitor clarithromycin with a calcium channel blocker (CCB) increased patients' odds of being hospitalized for acute kidney injury (OR=1.98) in a population-based retrospective cohort study of older adults (average age = 76 years) who were newly prescribed clarithromycin (n=96,226) or azithromycin (n=94,083) while receiving a CCB (amlodipine, felodipine, nifedipine, diltiazem, or verapamil - more than 50% amlodipine).<sup>3</sup> Secondary outcomes supported an association with a greater odds for hospitalization due to hypotension (0.12% vs 0.07%, OR=1.6), as well as with a greater odds for all-cause mortality (1.02% vs 0.59%, OR=1.74), in patients who were co-prescribed clarithromycin and CCBs. These results were consistent with another case-control study also involving older adults (n=7100) hospitalized for hypotension who had been co-prescribed a macrolide antibiotic while on a CCB (30% receiving amlodipine and 40% diltiazem).<sup>4</sup> Erythromycin, a moderate CYP3A4 inhibitor, and clarithromycin were both strongly associated with hypotension (OR=5.8 and OR=3.7, respectively), while azithromycin was not associated with increased odds for hypotension in this population.<sup>4</sup> In contrast, concurrent prescription of a CCB with clarithromycin was associated with only a non-statistically significant increase in the odds for nonvertebral fracture within 30 days of coprescription in a separate analysis of data from the same large retrospective cohort of 96,226 clarithromycin- and 94,083 azithromycin-recipients (OR=1.23; absolute risk difference=0.03%).<sup>5</sup> That these studies were restricted to older patients, included several different CCBs (even if amlodipine was the most or one of the most widely used CCBs), and included relatively uncommon outcomes make it unclear how clinically significant this interaction is, particularly in younger patients receiving such combinations. The amlodipine prescribing information states that coadministration may require an amlodipine dose reduction based on patient response but offers no more specific guidance.<sup>6</sup><br><br>Amlodipine appears to be metabolized by CYP3A4, suggesting that inhibition of this enzyme by strong CYP3A4 inhibitors is the likely mechanism for this interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lee JE, van Heeswijk R, Alves K, Smith F, Garg V. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. <i>Antimicrob Agents Chemother</i>. 2011;55(10):4569-4574. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21825288\">[PubMed 21825288]</a></p>\n<p>2. Glesby MJ, Aberg JA, Kendall MA, et al. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. <i>Clin Pharmacol Ther</i>. 2005;78(2):143-153. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16084849\">[PubMed 16084849]</a></p>\n<p>3. Gandhi S, Fleet JL, Bailey DG, et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. <i>JAMA</i>. 2013;310(23):2544-2553. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24346990\">[PubMed 24346990]</a></p>\n<p>4. Wright AJ, Gomes T, Mamdani MM, Horn JR, Juurlink DN. The risk of hypotension following coprescription of macrolide antibiotics and calcium-channel blockers. <i>CMAJ</i>. 2011;183(3):303-307. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21242274\">[PubMed 21242274]</a></p>\n<p>5. Fraser LA, Shariff SZ, McArthur E, Naylor KL, Garg AX. Calcium channel blocker-clarithromycin drug interaction did not increase the risk of nonvertebral fracture: a population-based study. <i>Ann Pharmacother</i>. 2015;49(2):185-188. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25429094\">[PubMed 25429094]</a></p>\n<p>6. Norvasc (amlodipine) [prescribing information]. New York, NY: Pfizer Inc; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10709":"<p><b>Title</b> Capecitabine / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Proton Pump Inhibitors may diminish the therapeutic effect of Capecitabine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Consider the need for a proton pump inhibitor in patients receiving capecitabine. If combined, monitor closely for any evidence of reduced capecitabine effectiveness with use of this combination.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> Concurrent use of a proton pump inhibitor (PPI) was associated with poorer progression-free survival (PFS) [4.2 months vs. 5.7 months, HR=1.55 (95% CI: 1.29 to 1.81)] and overall survival [9.2 months vs. 11.3 months, HR=1.34 (1.06 to 1.62)] among patients treated with capecitabine and oxaliplatin in a secondary analysis of the TRIO-013 (Translational Research in Oncology)/LOGiC (Lapatinib Optimization Study in the HER2-Positive Gastric Cancer) trial.<sup>1</sup> This analysis included a total of 545 patients, 42% of whom received 20% or more overlap of PPI treatment and study treatment duration. In the lapatinib arm of the study, PPI use was not associated with a significant difference in PFS or overall survival among patients treated with capecitabine and oxaliplatin plus lapatinib. These differences were generally similar in a multivariate analysis, with a significant difference in overall survival also emerging for patients treated with capecitabine and oxaliplatin plus lapatinib who did not receive a PPI (HR=1.38, p=0.03).<br><br>A retrospective analysis of patients treated with capecitabine for early-stage colorectal cancer aimed to determine if PPI use reduced capecitabine efficacy.<sup>2</sup> Among the 298 analyzed patients, 77 patients received, and 221 patients did not receive, a PPI during capecitabine therapy. Univariate analysis found that PPI use was associated with a decrease in 5-year recurrence-free survival [HR=1.89 (1.07 to 3.35)]. Although the authors concluded that a significant drug interaction exists between capecitabine and PPIs, after multivariate analysis and adjustment for gender, cancer stage, age, and ECOG performance scores, PPI use was no longer associated with a decrease in 5-year recurrence-free survival [HR 1.65 (0.93 to 2.94)]. Overall survival was unaffected by PPI use in both analyses.<br><br>The mechanism of this potential interaction is unknown. It has been hypothesized that the elevated gastric pH caused by PPI use may impair capecitabine tablet dissolution and/or reduce absorption.<sup>1,2</sup> In contrast, no significant pharmacokinetic interaction was observed when capecitabine was combined with a magnesium hydroxide and aluminum hydroxide containing antacid, with modest increases in capecitabine AUC and maximum serum concentration reported.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Chu MP, Hecht JR, Slamon D, et al. Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. <i>JAMA Oncol</i>. 2017;3(6):767-773. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27737436\">[PubMed 27737436]</a></p>\n<p>2. Sun J, Ilich AI, Kim CA, et al. Concomitant administration of proton pump inhibitors and capecitabine is associated with increased recurrence risk in early stage colorectal cancer patients. <i>Clin Colorectal Cancer</i>. 2016;15(3):257-263. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26803708\">[PubMed 26803708]</a></p>\n<p>3. Reigner B, Clive S, Cassidy J, et al. Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. <i>Cancer Chemother Pharmacol</i>. 1999;43(4):309-315. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10071982\">[PubMed 10071982]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10710":"<p><b>Title</b> AmLODIPine / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of AmLODIPine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for evidence of increased amlodipine effects or toxicity when used together with a moderate CYP3A4 inhibitor. Amlodipine dose reductions may be needed.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> According to one pharmacokinetic study, the amlodipine AUC was not significantly altered by the moderate CYP3A4 inhibitor erythromycin.<sup>1</sup> Others report an 8% to 16% increase in amlodipine AUC with the moderate inhibitor grapefruit juice,<sup>2,3</sup> and a 60% increase in amlodipine AUC with concurrent diltiazem, another moderate CYP3A4 inhibitor.<sup>1</sup> In contrast, pharmacokinetic studies have reported 1.9- to 2.8-fold higher amlodipine AUCs with concurrent use of the strong CYP3A4 inhibitors indinavir/ritonavir (800 mg/100 mg every 12 hours) and telaprevir (750 mg every 8 hours) in studies of healthy volunteers.<sup>4,5</sup><br><br>According to a case-control study involving older adults (n=7100) hospitalized for hypotension who had been co-prescribed a macrolide antibiotic while on a calcium channel blocker (CCB) (30% receiving amlodipine and 40% diltiazem), use of the moderate CYP3A4 inhibitor erythromycin and the strong CYP3A4 inhibitor clarithromycin were both strongly associated with hypotension (OR=5.8 and OR=3.7, respectively), while azithromycin, which is not a CYP3A4 inhibitor, was not associated with increased odds for hypotension in this population.<sup>6</sup> This and other similar studies of the CCB interaction with clarithromycin have been mixed in their findings regarding the clinical significance of this interaction.<sup>6,7,8</sup> That these studies were restricted to older patients, included several different CCBs (even if amlodipine was the most or one of the most widely used CCBs), and included relatively uncommon outcomes make it additionally unclear how clinically significant this interaction is, particularly in younger patients receiving such combinations. The amlodipine prescribing information states that coadministration may require an amlodipine dose reduction based on patient response but offers no more specific guidance.<sup>1</sup><br><br>Amlodipine appears to be metabolized by CYP3A4, suggesting that inhibition of this enzyme by strong CYP3A4 inhibitors is the likely mechanism for this interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Norvasc (amlodipine) [prescribing information]. New York, NY: Pfizer Inc; March 2015.</p>\n<p>2. Josefsson M, Zackrisson AL, Ahlner J. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. <i>Eur J Clin Pharmacol</i>. 1996;51(2):189-193. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8911887\">[PubMed 8911887]</a></p>\n<p>3. Vincent J, Harris SI, Foulds G, Dogolo LC, Willavize S, Friedman HL. Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. <i>Br J Clin Pharmacol</i>. 2000;50(5):455-463. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11069440\">[PubMed 11069440]</a></p>\n<p>4. Lee JE, van Heeswijk R, Alves K, Smith F, Garg V. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. <i>Antimicrob Agents Chemother</i>. 2011;55(10):4569-4574. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21825288\">[PubMed 21825288]</a></p>\n<p>5. Glesby MJ, Aberg JA, Kendall MA, et al. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. <i>Clin Pharmacol Ther</i>. 2005;78(2):143-153. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16084849\">[PubMed 16084849]</a></p>\n<p>6. Wright AJ, Gomes T, Mamdani MM, Horn JR, Juurlink DN. The risk of hypotension following coprescription of macrolide antibiotics and calcium-channel blockers. <i>CMAJ</i>. 2011;183(3):303-307. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21242274\">[PubMed 21242274]</a></p>\n<p>7. Gandhi S, Fleet JL, Bailey DG, et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. <i>JAMA</i>. 2013;310(23):2544-2553. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24346990\">[PubMed 24346990]</a></p>\n<p>8. Fraser LA, Shariff SZ, McArthur E, Naylor KL, Garg AX. Calcium channel blocker-clarithromycin drug interaction did not increase the risk of nonvertebral fracture: a population-based study. <i>Ann Pharmacother</i>. 2015;49(2):185-188. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25429094\">[PubMed 25429094]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10711":"<p><b>Title</b> Zolpidem / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Zolpidem. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased zolpidem effectiveness if combined with strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The AUC of zolpidem (20 mg single dose) was decreased by an average of 73% in 8 healthy female volunteers when administered following a 5-day course of rifampin (600 mg/day).<sup>1</sup> The average maximum serum concentration (Cmax) was decreased by 58%, and the average half-life was decreased by 30%. Several tests of zolpidem pharmacodynamics also suggested significantly impaired effectiveness.<sup>1</sup> In a clinical study of 18 healthy volunteers, administration of carbamazepine (400 mg orally daily for 15 days) decreased the Cmax and AUC of zolpidem (5 mg single oral dose) by 41% and 57%, respectively.<sup>2</sup><br><br>Zolpidem prescribing information states that the combined use of zolpidem and CYP3A4 inducers may decrease the efficacy of zolpidem.<sup>3</sup> <br><br>The mechanism of this interaction is likely due to the induction of CYP3A4, an enzyme responsible for zolpidem metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Villikka K, Kivisto KT, Luurila H, Neuvonen PJ. Rifampin reduces plasma concentrations and effects of zolpidem. <i>Clin Pharmacol Ther</i>. 1997;62(6):629-634. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9433391\">[PubMed 9433391]</a></p>\n<p>2. Vlase L, Popa A, Neag M, Muntean D, Baldea I, Leucuta SE. Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. <i>J Clin Pharmacol</i>. 2011;51(8):1233-1236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21098143\">[PubMed 21098143]</a></p>\n<p>3. Ambien (zolpidem) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; August 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10712":"<p><b>Title</b> Zolpidem / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zolpidem. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased zolpidem effectiveness if combined with moderate CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 14 healthy male volunteers, zolpidem (10 mg single dose) AUC and maximum serum concentration decreased by 30% and 34%, respectively, when coadministered with St. John’s wort (300 mg three times daily x 14 days).<sup>1</sup><br><br>Zolpidem prescribing information states that the combined use of zolpidem and CYP3A4 inducers may decrease the efficacy of zolpidem.<sup>2</sup><br><br>The mechanism of this interaction is likely due to the induction of CYP3A4, an enzyme responsible for zolpidem metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hojo Y, Echizenya M, Ohkubo T, Shimizu T. Drug interaction between St John's wort and zolpidem in healthy subjects. <i>J Clin Pharm Ther</i>. 2011;36(6):711-715. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21058968\">[PubMed 21058968]</a></p>\n<p>2. Ambien (zolpidem) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; August 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10713":"<p><b>Title</b> Antineoplastic Agents / Palifermin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Palifermin may enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral mucositis may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.</p>\n<div>\n <p><b>Antineoplastic Agents Interacting Members</b> Altretamine, Amsacrine, AzaCITIDine, Belotecan, Bendamustine, Bleomycin, Busulfan, Cabazitaxel, Capecitabine, CARBOplatin, Carmustine, Chlorambucil, CISplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine (Conventional), Dacarbazine, DACTINomycin, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Decitabine, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), EpiRUBicin, EriBULin, Estramustine, Etoposide, Etoposide Phosphate, Floxuridine, Fludarabine, Fluorouracil (Systemic), Fotemustine, Gemcitabine, Hydroxyurea, IDArubicin, Ifosfamide, Irinotecan (Conventional), Irinotecan (Liposomal), Ixabepilone, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, Methotrexate, MitoMYcin (Systemic), MitoXANTRONE, Nelarabine, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), PEMEtrexed, Pentostatin, Pixantrone, PRALAtrexate, Procarbazine, Raltitrexed, Streptozocin, Tegafur, Temozolomide, Teniposide, Thioguanine, Thiotepa, Topotecan, Trabectedin, Treosulfan, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine</p>\n</div> \n<p><b>Discussion</b> In one arm of a clinical trial evaluating the safety and efficacy of palifermin, patients received palifermin daily for 3 days prior to total body irradiation, on the last day of total body irradiation prior to etoposide, and daily for 3 days following stem cell infusion or placebo.<sup>1</sup> This study arm was terminated early due to the lack of palifermin therapeutic efficacy and a trend toward increased severity and duration of oral mucositis compared to patients receiving placebo.<sup>1</sup> <br><br>Palifermin prescribing information states that palifermin should not be administered within 24 hours before, during the infusion of, or within 24 hours after the administration of myelotoxic chemotherapy.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated but it has been hypothesized that the administration of palifermin within 24 hours of chemotherapy resulted in an increased sensitivity of the rapidly dividing epithelial cells in the immediate post-chemotherapy period.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kepivance (palifermin) [prescribing information]. Stockholm, Sweden: Swedish Orphan Biovitrum AB; July 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10714":"<p><b>Title</b> Bedaquiline / Clofazimine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Clofazimine may enhance the QTc-prolonging effect of Bedaquiline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for QTc prolongation and torsade de pointes if bedaquiline and clofazimine are combined.</p> \n<p><b>Discussion</b> A US Food and Drug Administration safety alert states that QTc prolongation has been reported in patients receiving clofazimine with bedaquiline at the recommended dosage regimen for each drug.<sup>1</sup> Electrocardiograms (ECGs) should be monitored if clofazimine is coadministered with bedaquiline, and both drugs should be discontinued if a clinically significant ventricular arrhythmia is noted or if the QTc interval is 500 milliseconds or greater.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. US Food and Drug Administration. FDA Drug Safety Communication: Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER): Lamprene (clofazimine). http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm514749.htm. Published July 1, 2016. Accessed August 25, 2016.</p>\n<p>2. Sirturo (bedaquiline) [prescribing information]. Titusville, NJ: Janssen Therapeutics; December 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10715":"<p><b>Title</b> Topotecan / Granulocyte Colony-Stimulating Factors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Granulocyte Colony-Stimulating Factors may enhance the myelosuppressive effect of Topotecan. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Topotecan prescribing information recommends not administering granulocyte colony-stimulating factor (G-CSF) until at least 24 hours after the last dose of topotecan. Monitor neutrophil counts and for signs/symptoms of neutropenic fever closely in patients receiving topotecan with G-CSF.</p>\n<div>\n <p><b>Granulocyte Colony-Stimulating Factors Interacting Members</b> Filgrastim, Lenograstim, Lipegfilgrastim, Pegfilgrastim</p>\n</div> \n<p><b>Discussion</b> Prolonged neutropenia associated with combined administration of granulocyte colony-stimulating factor (G-CSF) with topotecan is described in the topotecan product labeling.<sup>1</sup> One published report describes severe myelosuppression occuring after administration of topotecan (2.0mg/m<sup>2</sup>/day for 5 days every 3 weeks) with filgrastim (5 mcg/kg/d) starting on day 1 in 36 patients being treated for solid tumors.<sup>2</sup> Delaying filgrastim administration until day 6 (24 hours after the last dose of topotecan) did allow topotecan dose-escalation to the targeted level (2.3-fold greater dose than with filgrastim use on day 1). The mechanism of this reported interaction is unclear, but the immature neutrophils formed following G-CSF may be more sensitive to the cytotoxic effects of topotecan.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hycamtin (topotecan) [prescribing Information]. Research Triangle Park, NC: GlaxoSmithKline; June 2015.</p>\n<p>2. Rowinsky EK, Grochow LB, Sartorius SE, et al. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. <i>J Clin Oncol</i>. 1996;14(4):1224-1235. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8648378\">[PubMed 8648378]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10716":"<p><b>Title</b> Belotecan / Granulocyte Colony-Stimulating Factors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Granulocyte Colony-Stimulating Factors may enhance the neutropenic effect of Belotecan. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Belotecan labeling recommends not administering granulocyte colony-stimulating factor (G-CSF) until at least 24 hours after completion of belotecan administration. Monitor neutrophil counts and signs/symptoms of neutropenic fever closely in patients receiving belotecan with G-CSF.</p>\n<div>\n <p><b>Granulocyte Colony-Stimulating Factors Interacting Members</b> Filgrastim, Lenograstim, Lipegfilgrastim, Pegfilgrastim</p>\n</div> \n<p><b>Discussion</b> The belotecan labeling cautions that prolonged neutropenia may be associated with combined administration of granulocyte colony-stimulating factor (G-CSF) and belotecan.<sup>1</sup> One published report describes severe myelosuppression occuring after administration of the related compound topotecan (2.0mg/m<sup>2</sup>/day for 5 days every 3 weeks) with filgrastim (5 mcg/kg/d) starting on day 1 in 36 patients being treated for solid tumors.<sup>2</sup> Delaying filgrastim administration until day 6 (24 hours after the last dose of topotecan) did allow topotecan dose-escalation to the targeted level (2.3-fold greater dose than with filgrastim use on day 1). The mechanism of this reported interaction is unclear, but the immature neutrophils formed following G-CSF may be more sensitive to the cytotoxic effects of agents such as topotecan or belotecan.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Belotecan [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200300087. Accessed on March 13, 2015.</p>\n<p>2. Rowinsky EK, Grochow LB, Sartorius SE, et al. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. <i>J Clin Oncol</i>. 1996;14(4):1224-1235. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8648378\">[PubMed 8648378]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10717":"<p><b>Title</b> Amdinocillin / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Valproate Products may enhance the adverse/toxic effect of Amdinocillin. Specifically, the risk for carnitine deficiency may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of amdinocillin (aka pivmecillinam) with valproate products should be avoided due to the risk of carnitine depletion.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> The labeling for amdinocillin (aka pivmecillinam) states that concurrent use of valproate products or other medications that can liberate pivalic acid should be avoided due to the risk of carnitine depletion.<sup>1</sup> Pivalate is primarily excreted in the form of pivaloylcarnitine, resulting in a reduction in carnitine,<sup>2</sup> which is an effect that could be exacerbated with concurrent use of other drugs that have been associated with carnitine depletion, such as valproate products.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Selexid (pivmecillinam) [summary of product characteristics]. Hurley, Berkshire, United Kingdom: LEO Laboratories Limited; May 2016.</p>\n<p>2. Brass EP. Pivalate-generating prodrugs and carnitine homeostasis in man. <i>Pharmacol Rev</i>. 2002;54(4):589-598. Review. PubMed PMID: 12429869.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10718":"<p><b>Title</b> Amdinocillin / Erythromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Erythromycin (Systemic) may diminish the therapeutic effect of Amdinocillin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of amdinocillin (aka pivmecillinam) if used concomitantly with erythromycin.</p> \n<p><b>Discussion</b> The labeling for amdinocillin (aka pivmecillinam) states that bacteriostatic agents such as erythromycin and tetracyclines may interfere with the bactericidal effects of penicillins.<sup>1</sup><br><br>Specific data concerning this combination with erythromycin are limited, but at least one in vitro study reports evidence supporting this potential interaction,<sup>2</sup> and considerably more supportive data exists with tetracyclines.<br><br>Efficacy in treating pneumococcal meningitis revealed that patients receiving penicillin alone showed a reduced rate of mortality compared to patients receiving penicillin plus a tetracycline (chlortetracycline, oxytetracycline, tetracycline).<sup>3,4</sup> Furthermore, studies evaluating the use of amoxicillin and tetracycline as part of H. Pylori regimen found significantly reduced rates of eradication in therapies containing amoxicillin and tetracycline, when compared to control regimens.<sup>5,6</sup><br><br>A likely mechanism of this interaction is the antagonistic effects of bacteriostatic tetracyclines on bacteriacidal penicillins. Penicillins exhibit optimal bacterial killing on dividing cells, which tetracyclines inhibit, thus reducing the efficacy of penicillins. There are in vitro data both supporting and refuting this interaction.<sup>7,8,9</sup> Additionally, not all studies have found decrease efficacy with concurrent tetracycline and penicillin therapy. For example, one study found that adding tetracycline (500 mg oxytetracycline every 6 hours for 7 days) to a single dose of ampicillin (2 g) and probenecid (1 g) in patients with gonorrhea beneficial.<sup>10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Selexid (pivmecillinam) [summary of product characteristics]. Hurley, Berkshire, United Kingdom: LEO Laboratories Limited; May 2016.</p>\n<p>2. Johansen HK, Jensen TG, Dessau RB, Lundgren B, Frimodt-Moller N. Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo. <i>J Antimicrob Chemother</i>. 2000;46(6):973-980. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11102417\">[PubMed 11102417]</a></p>\n<p>3. Lepper MH, Dowling HF. Treatment of pneumococcic meningitis with penicillin compared with penicillin plus aureomycin; studies including observations on an apparent antagonism between penicillin and aureomycin. <i>AMA Arch Intern Med</i>. 1951;88(4):489-494. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14867955\">[PubMed 14867955]</a></p>\n<p>4. Olsson RA, Kirby JC, and Romansky MJ. Pneumococcal meningitis in the adult. Clinical, therapeutic, and prognostic aspects in forty-three patients. <i>Ann Intern Med</i>. 1961;55:545-549. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14481954\">[PubMed 14481954]</a></p>\n<p>5. Cheon JH, Kim SG, Kim JM, et al. Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility. <i>J Gastroenterol Hepatol</i>. 2006;21(10):1590-1595. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16928222\">[PubMed 16928222]</a></p>\n<p>6. Perri F, Festa V, Merla A, Quitadamo M, Clemente R, Andriulli A. Amoxicillin/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection. <i>Helicobacter</i>. 2002;7(2):99-104. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11966868\">[PubMed 11966868]</a></p>\n<p>7. Li RC, Schentag JJ, Nix DE. The fractional maximal effect method: a new way to characterize the effect of antibiotic combinations and other nonlinear pharmacodynamic interactions. <i>Antimicrob Agents Chemother</i>. 1993;37(3):523-531. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8460921\">[PubMed 8460921]</a></p>\n<p>8. Elek SD, Hilson GF, Jewell P. Laboratory aspects of combined antibiotic treatment. <i>Br Med J</i>. 1953;2(4849):1298-1300. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13106416\">[PubMed 13106416]</a></p>\n<p>9. Daschner FD. Combination of bacteriostatic and bactericidal drugs: lack of significant in vitro antagonism between penicillin, cephalothin, and rolitetracycline. <i>Antimicrob Agents Chemother</i>. 1976;10(5):802-808. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=795370\">[PubMed 795370]</a></p>\n<p>10. Ridgway GL, Oriel JD. Advantages of adding a course of tetracycline to single dose ampicillin and probenecid in the treatment of gonorrhoea. <i>Br J Vener Dis</i>. 1984;60(4):235-237. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6744010\">[PubMed 6744010]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10719":"<p><b>Title</b> SUNItinib / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of SUNItinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Advise patients to avoid consuming grapefruit and grapefruit juice during sunitinib treatment.</p> \n<p><b>Discussion</b> Sunitinib US prescribing information states that grapefruit may increase sunitinib plasma concentrations, and that patients should avoid grapefruit and grapefruit juice during sunitinib treatment.<sup>1</sup> In a clinical study of 8 patients receiving sunitinib, consumption of grapefruit juice (200 mL 3 times daily for 3 days) increased the estimated sunitinib relative bioavailability by 11%.<sup>2</sup> The suspected mechanism of this interaction is inhibition of intestinal P-glycoprotein-mediated sunitinib efflux and/or CYP3A-mediated sunitinib metabolism by grapefruit components.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sutent (sunitinib) [prescribing information]. New York, NY: Pfizer Inc; November 2015.</p>\n<p>2. van Erp NP, Baker SD, Zandvliet AS, et al. Marginal increase of sunitinib exposure by grapefruit juice. <i>Cancer Chemother Pharmacol</i>. 2011;67(3):695-703. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20512335\">[PubMed 20512335]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10720":"<p><b>Title</b> Gliclazide / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Gliclazide. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased gliclazide effects (eg, hyperglycemia, loss of blood glucose control) if combined with St John's wort.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 21 healthy volunteers, St John's wort (300 mg three times daily x 15 days) decreased the gliclazide (80 mg single dose) AUC and maximum serum concentration 33% and 22%, respectively.<sup>1</sup> The glucose lowering effects of gliclazide were unchanged in the presence of St John's wort.<sup>1</sup><br><br>Gliclazide product labeling states that an interaction between gliclazide and St John’s wort may occur and may lead to hyperglycemia or loss of blood glucose control.<sup>2</sup><br><br>The mechanism of this potential interaction has not been investigated, but induction of the CYP enzymes involved in gliclazide metabolism by St John's wort likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Xu H, Williams KM, Liauw WS, Murray M, Day RO, McLachlan AJ. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide.<i>Br J Pharmacol</i>. 2008;153(7):1579-1586. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18204476\">[PubMed 18204476]</a></p>\n<p>2. Diamicron (gliclazide) [product monograph]. Laval, Quebec, Canada: Servier Canada Inc; July 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10721":"<p><b>Title</b> CYP2D6 Substrates (High risk with Inhibitors) / QuiNINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> QuiNINE may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects/toxicities of CYP2D6 substrates (or decreased effects for prodrugs activated by CYP2D6) if combined with quinine. Higher doses of quinine (greater than or equal to 600 mg) are more likely to interact than lower doses.</p>\n<div>\n <p><b>CYP2D6 Substrates (High risk with Inhibitors) Interacting Members</b> Ajmaline, Amitriptyline, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, AtoMOXetine, Brexpiprazole, Captopril, Carvedilol, Chloroquine, Chlorpheniramine, ChlorproMAZINE, ClomiPRAMINE, Codeine, Dapoxetine, Desipramine, Deutetrabenazine, Dextromethorphan, Doxepin (Systemic), Doxepin (Topical), DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eliglustat, Flecainide, FLUoxetine, FluPHENAZine, FluvoxaMINE, Gefitinib, Haloperidol, Iloperidone, Imipramine, Indoramin, Maprotiline, Mequitazine, Methamphetamine, Metoprolol, Mexiletine, Mirtazapine, Nefazodone, Nortriptyline, Olmutinib, PARoxetine, Perhexiline, Perphenazine, Pimozide, Primaquine, Procainamide, Propafenone, Propranolol, Protriptyline, RisperiDONE, Syrian Rue, Tamoxifen, Tetrabenazine, Thioridazine, Timolol (Ophthalmic), Timolol (Systemic), Tolterodine, Trimipramine, Tropisetron, Venlafaxine, Vortioxetine, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 7 CYP2D6 extensive metabolizers, coadministration of quinine (750 mg daily x 2 days) and the CYP2D6 substrate desipramine (25 mg single dose) decreased the urinary excretion of the 2-OH-desipramine metabolite by 54%.<sup>1</sup> In contrast, quinine (80 mg or 400 mg) had no effect on the metabolism of debrisoquine or dextromethorphan (known CYP2D6 probe substrates).<sup>2,3</sup> <br><br>Quinine prescribing information states that although clinical drug interaction studies have not been performed, antimalarial doses (greater than or equal to 600 mg) of<br>quinine may inhibit the metabolism of other drugs that are CYP2D6 substrates (eg, flecainide, debrisoquine, dextromethorphan, metoprolol, paroxetine). Patients taking medications that are CYP2D6 substrates with quinine should be monitored closely for adverse reactions associated with these medications.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Steiner E, Dumont E, Spina E, Dahlqvist R. Inhibition of desipramine 2-hydroxylation by quinidine and quinine. <i>Clin Pharmacol Ther</i>. 1988;43(5):577-581. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3365919\">[PubMed 3365919]</a></p>\n<p>2. Donovan JL, DeVane CL, Boulton D, Dodd S, Markowitz JS. Dietary levels of quinine in tonic water do not inhibit CYP2D6 in vivo. <i>Food Chem Toxicol</i>. 2003;41(8):1199-1201. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12842189\">[PubMed 12842189]</a></p>\n<p>3. Ayesh R, Dawling S, Hayler A, et al. Comparative effects of the diastereoisomers quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers. <i>Chirality</i>. 1991;3(1):14-18. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2039678\">[PubMed 2039678]</a></p>\n<p>4. Qualaquin (quinine) [prescribing information]. Philadelphia, PA: Mutual Pharmaceutical Company Inc; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10722":"<p><b>Title</b> CYP2D6 Substrates (High risk with Inhibitors) / Lumefantrine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Lumefantrine may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects/toxicities of CYP2D6 substrates (or decreased effects for prodrugs activated by CYP2D6) if combined with lumefantrine.</p>\n<div>\n <p><b>CYP2D6 Substrates (High risk with Inhibitors) Interacting Members</b> Ajmaline, Amitriptyline, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, AtoMOXetine, Brexpiprazole, Captopril, Carvedilol, Chloroquine, Chlorpheniramine, ChlorproMAZINE, ClomiPRAMINE, Codeine, Dapoxetine, Desipramine, Deutetrabenazine, Dextromethorphan, Doxepin (Systemic), Doxepin (Topical), DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eliglustat, Flecainide, FLUoxetine, FluPHENAZine, FluvoxaMINE, Gefitinib, Haloperidol, Iloperidone, Imipramine, Indoramin, Maprotiline, Mequitazine, Methamphetamine, Metoprolol, Mexiletine, Mirtazapine, Nefazodone, Nortriptyline, Olmutinib, PARoxetine, Perhexiline, Perphenazine, Pimozide, Primaquine, Procainamide, Propafenone, Propranolol, Protriptyline, RisperiDONE, Syrian Rue, Tamoxifen, Tetrabenazine, Thioridazine, Timolol (Ophthalmic), Timolol (Systemic), Tolterodine, Trimipramine, Tropisetron, Venlafaxine, Vortioxetine, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> In vitro data indicate that lumefantrine may inhibit CYP2D6, but no human studies have been conducted to assess the potential for lumefantrine to increase serum concentrations of CYP2D6 substrates in humans.<sup>1</sup> <br><br>The artemether/lumefantrine prescribing information states that because lumefantrine inhibits CYP2D6 in vitro, administration with drugs that are metabolized by CYP2D6 may significantly increase plasma concentrations of the coadministered drug and increase the risk of adverse effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Coartem (artemether/lumefantrine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10723":"<p><b>Title</b> CYP2D6 Substrates (High risk with Inhibitors) / Imatinib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Imatinib may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects/toxicities of CYP2D6 substrates (or decreased effects for prodrugs activated by CYP2D6) if combined with imatinib. Particular caution should be used when administering imatinib with CYP2D6 substrates that have a narrow therapeutic index.</p>\n<div>\n <p><b>CYP2D6 Substrates (High risk with Inhibitors) Interacting Members</b> Ajmaline, Amitriptyline, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, AtoMOXetine, Brexpiprazole, Captopril, Carvedilol, Chloroquine, Chlorpheniramine, ChlorproMAZINE, ClomiPRAMINE, Codeine, Dapoxetine, Desipramine, Deutetrabenazine, Dextromethorphan, Doxepin (Systemic), Doxepin (Topical), DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eliglustat, Flecainide, FLUoxetine, FluPHENAZine, FluvoxaMINE, Gefitinib, Haloperidol, Iloperidone, Imipramine, Indoramin, Maprotiline, Mequitazine, Methamphetamine, Metoprolol, Mexiletine, Mirtazapine, Nefazodone, Nortriptyline, Olmutinib, PARoxetine, Perhexiline, Perphenazine, Pimozide, Primaquine, Procainamide, Propafenone, Propranolol, Protriptyline, RisperiDONE, Syrian Rue, Tamoxifen, Tetrabenazine, Thioridazine, Timolol (Ophthalmic), Timolol (Systemic), Tolterodine, Trimipramine, Tropisetron, Venlafaxine, Vortioxetine, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 20 patients with chronic myeloid leukemia, imatinib (400 mg twice daily x 9 days) increased the CYP2D6 substrate metoprolol (100 mg single dose) AUC 23%.<sup>1,2</sup><br><br>Imatinib prescribing information states that imatinib has a weak inhibitory effect on CYP2D6-mediated metabolism.<sup>2</sup> No dose adjustment is necessary, however, caution is recommended when administering imatinib with CYP2D6 substrates that have a narrow therapeutic index.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Wang Y, Zhou L, Dutreix C, et al. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukemia. <i>Br J Clin Pharmacol</i>. 2008;65(6):885-892. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18384443\">[PubMed 18384443]</a></p>\n<p>2. Gleevec (imatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; August 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10724":"<p><b>Title</b> BCRP/ABCG2 Substrates / Regorafenib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Regorafenib may increase the serum concentration of BCRP/ABCG2 Substrates. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects/toxicities of BCRP substrates if combined with regorafenib.</p>\n<div>\n <p><b>BCRP/ABCG2 Substrates Interacting Members</b> Glecaprevir and Pibrentasvir, PAZOPanib, Rosuvastatin, SulfaSALAzine, Topotecan</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the regorafenib prescribing information, regorafenib (160 mg daily x 14 days) increased the rosuvastatin (5 mg single dose) AUC and maximum serum concentration 3.8-fold and 4.6-fold, respectively.<sup>1</sup><br><br>Regorafenib prescribing information states that concomitant use of regorafenib and a BCRP substrate may lead to increased exposure of the BCRP substrate.<sup>1</sup> Monitor for exposure-related toxicities of the BCRP substrate if combined with regorafenib.<sup>1</sup><br><br>The mechanism of this interaction is likely due to regorafenib inhibition of BCRP, a transporter responsible for rosuvastatin disposition. Regorafenib inhibition of CYP2C9 may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stivarga (regorafenib) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; August 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10733":"<p><b>Title</b> Imatinib / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Imatinib. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 4 patients receiving chronic treatment with imatinib (400 mg daily), the administration of grapefruit juice (250 mL daily for 7 days) resulted in no change to the pharmacokinetic parameters of imatinib.<sup>1</sup> The authors hypothesized that because the absolute bioavailability of imatinib is nearly 100%, inhibition of intestinal CYP3A4 by grapefruit juice could not further increase imatinib absorption.<sup>1</sup><br><br>However, imatinib prescribing information states that grapefruit juice may increase plasma concentrations of imatinib and patients should avoid grapefruit juice during imatinib treatment.<sup>2</sup><br><br>The suspected primary mechanism of this interaction is grapefruit juice-mediated inhibition of CYP3A4, an enzyme responsible for imatinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gleevec (imatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10734":"<p><b>Title</b> Opioid Analgesics / CNS Depressants</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug to the minimum possible while achieving the desired clinical effect. Warn patients and caregivers about the risk of slowed or difficult breathing and/or sedation. A separate FDA safety communication says patents requiring methadone or buprenorphine for treatment of opioid dependence should not be excluded from such treatment due to the concomitant use of a CNS depressant. Close monitoring for adverse effects with any combined use is warranted.</p>\n<div>\n <p><b>Opioid Analgesics Interacting Members</b> Alfentanil, Benzhydrocodone, Buprenorphine, Butorphanol, Codeine, Dihydrocodeine, FentaNYL, Heroin, HYDROcodone, HYDROmorphone, Levorphanol, Meperidine, Meptazinol, Methadone, Morphine (Liposomal), Morphine (Systemic), Nalbuphine, Opium, Opium Tincture, OxyCODONE, OxyMORphone, Paregoric, Pentazocine, Remifentanil, SUFentanil, Tapentadol, TraMADol</p>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The US Food and Drug Administration (FDA) issued a drug safety communication stating that the combined use of opioid medicines with benzodiazepines or other drugs that depress the CNS has resulted in serious side effects, including slowed or difficult breathing and deaths.<sup>1</sup> The labels of all opioid medications and benzodiazepines will be updated to include a boxed warning describing this alert.<sup>1</sup> Another FDA safety communication recommends that patients should not be excluded from treatment with methadone or buprenorphine for opioid dependence due to concomitant use of CNS depressants, considering both the potential risks of this combination and the potential risks associated with untreated opioid dependence.<sup>2</sup><br><br>A cohort study conducted in North Carolina found that the risk of opioid-related overdose death was 10-fold higher in patients who also received benzodiazepines (7.0 per 10,000 person-years; 95% CI 6.3 to 7.8) compared with patients who received opioids alone (0.7 per 10,000 person years; 95% CI 0.6 to 0.9).<sup>3</sup> In another analysis of patients receiving opioids in the Veterans Health Administration database, the risk of death from drug overdose was significantly higher among patients prescribed concomitant benzodiazepines compared with those receiving opioids alone (hazard ratio (HR) 3.86; 95% CI 3.49 to 4.26).<sup>4</sup> A cohort study of 4501 Swedish patients prescribed buprenorphine or methadone for treatment of opioid dependence reported an increased risk of both overdose-related deaths (adjusted HR 1.49 to 2.02) and all-cause mortality (adjusted HR 1.28 to 2.01) for patients receiving concurrent benzodiazepines, z-drugs (zopiclone, zolpidem, or zaleplon), or pregabalin.<sup>5</sup> Not all of these increases were statistically significant, but the overall picture of a general increased risk with these combinations is consistent with other data. The odds of opioid-related death was also significantly increased in opioid-treated patients who were exposed to gabapentin within 120 days (adjusted OR 1.49; 95% CI 1.18 to 1.88) as compared with those taking an opioid prescription alone, according to a case-control study of 1,256 cases (individuals who died of an opioid-related cause) and 4,619 matched controls (opioid users).<sup>6</sup> Secondary analyses found evidence of gabapentin dose-dependency (ie, a greater increase in odds with higher vs. lower gabapentin doses), as well as similar results when restricting the analysis to gabapentin users where the days supply overlapped the date of the opioid-related death. <br><br>Additional analyses have concluded that other CNS depressants (eg, antipsychotics, antidepressants, antiepileptics) and alcohol are often implicated in opioid-related overdose and death.<sup>7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. http://www.fda.gov/Drugs/DrugSafety/ucm518473.htm. Published August 31, 2016. Accessed September 8, 2016.</p>\n<p>2. FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. https://www.fda.gov/Drugs/DrugSafety/ucm575307.htm. Accessed September 21, 2017.</p>\n<p>3. Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. <i>Pain Med</i>. 2016;17(1):85-98. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26333030\">[PubMed 26333030]</a></p>\n<p>4. Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study [published online June 10, 2015]. <i>BMJ</i>. doi: 10.1136/bmj.h2698. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26063215\">[PubMed 26063215]</a></p>\n<p>5. Abrahamsson, Berge J, Ojehagen A, Hakansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. <i>Drug Alcohol Depend</i>. 2017;174:58-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28315808\">[PubMed 28315808]</a></p>\n<p>6. Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. <i>PLoS Med</i>. 2017;14(10):e1002396. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28972983\">[PubMed 28972983]</a></p>\n<p>7. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. <i>JAMA</i>. 2013;309(7):657-659. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23423407\">[PubMed 23423407]</a></p>\n<p>8. Jones CM, Paulozzi LJ, Mack KA; Centers for Disease Control and Prevention (CDC). Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths-United States, 2010. <i>MMWR Morb Mortal Wkly Rep</i>. 2014;63(40):881-885. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25299603\">[PubMed 25299603]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10735":"<p><b>Title</b> Reserpine / Pizotifen</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pizotifen may diminish the antihypertensive effect of Reserpine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased reserpine efficacy if combined with pizotifen.</p> \n<p><b>Discussion</b> A case report describes a 26-year-old man treated with debrisoquine (30 mg every 8 hours), furosemide (40 mg daily), and timolol (10 mg every 8 hours) whose blood pressure was adequately controlled (130/90 mm Hg).<sup>1</sup> After initiation of pizotifen (initially 1.5 mg per day, then increased to 2.5 mg per day), his blood pressure steadily rose from 160/112 mm Hg to 195/145 mm Hg. After pizotifen discontinuation, his blood pressure decreased to 140/90 mm Hg.<sup>1</sup><br><br>Pizotifen product labeling states that pizotifen may reduce the efficacy of adrenergic neuronal blocking agents (eg, reserpine, debrisoquine, guanethidine) as it antagonizes their hypotensive effect.<sup>2</sup> Patient blood pressure monitoring is recommended.<sup>2</sup><br><br>The mechanism of this interaction has not been fully investigated.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bailey RR. Antagonism of debrisoquine sulfate by pizotifen (Sandomigran). <i>N Z Med J</i>. 1976;83(566):499. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1067495\">[PubMed 1067495]</a></p>\n<p>2. Sandomigran (pizotifen) [product monograph]. Montreal, Quebec, Canada: Paladin Labs Inc; October 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10736":"<p><b>Title</b> Indoramin / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the sedative effect of Indoramin. Alcohol (Ethyl) may increase the serum concentration of Indoramin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased indoramin effects (eg, hypotension, sedation) if combined with alcohol.</p> \n<p><b>Discussion</b> In a study of healthy volunteers, coadministration of oral indoramin (50 mg single dose) and ethanol (0.5 g/kg consumed over 10 minutes) increased the indoramin AUC and maximum serum concentration 25% and 58%, respectively.<sup>1</sup> Ethanol did not alter the pharmacokinetics of intravenous indoramin.<sup>1</sup> The combination of indoramin (oral or intravenous) and ethanol resulted in higher sedation scores than those of indoramin alone.<sup>1</sup><br><br>Indoramin product labeling states that alcohol can increase indoramin absorption.<sup>2,3</sup> One product label recommends avoiding the use of alcohol with indoramin,<sup>2</sup> while another states that adverse effects are unlikely to occur with this combination.<sup>3</sup><br><br>The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Abrams SM, Pierce DM, Johnston A, Hedges A, Franklin RA, Turner P. Pharmacokinetic interaction between indoramin and ethanol. <i>Hum Toxicol</i>. 8(3):237-241. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2744781\">[PubMed 2744781]</a></p>\n<p>2. Doralese Tiltab (indoramin) [summary of product characteristics]. Surrey, UK: Chemidex Pharmac Ltd; November 2015.</p>\n<p>3. Baratol (indoramin) [summary of product characteristics]. London, UK: Concordia International; December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10737":"<p><b>Title</b> Indoramin / CYP2D6 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may increase the serum concentration of Indoramin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased indoramin effects (ie, hypotension) when combined with CYP2D6 inhibitors.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of healthy volunteers, the AUC and maximum serum concentration of indoramin (50 mg single dose) were 17-fold and 6.3-fold higher in 5 CYP2D6 poor metabolizers compared with 7 CYP2D6 extensive metabolizers, suggesting that indoramin elimination is highly dependent on CYP2D6 metabolism.<sup>1</sup> Use of indoramin with strong CYP2D6 inhibitors would be expected to increase indoramin serum concentrations in a similar manner to those seen in poor CYP2D6 metabolizers.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pierce DM, Smith SE, Franklin RA. The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. <i>Eur J Clin Pharmacol</i>. 1987;33(1):59-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3691597\">[PubMed 3691597]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10738":"<p><b>Title</b> Indoramin / CYP2D6 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Indoramin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased indoramin effects (ie, hypotension) when combined with CYP2D6 inhibitors.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Moderate) Interacting Members</b> Abiraterone Acetate, Asunaprevir, BuPROPion, Cinacalcet, Darifenacin, Darunavir, DULoxetine, Lorcaserin, Mirabegron, Perhexiline, Rolapitant, Terbinafine (Systemic), Thioridazine</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of healthy volunteers, the AUC and maximum serum concentration of indoramin (50 mg single dose) were 17-fold and 6.3-fold higher in 5 CYP2D6 poor metabolizers compared with 7 CYP2D6 extensive metabolizers, suggesting that indoramin elimination is highly dependent on CYP2D6 metabolism.<sup>1</sup> Use of indoramin with moderate CYP2D6 inhibitors would be expected to increase indoramin serum concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pierce DM, Smith SE, Franklin RA. The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. <i>Eur J Clin Pharmacol</i>. 1987;33(1):59-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3691597\">[PubMed 3691597]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10739":"<p><b>Title</b> Indoramin / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the hypotensive effect of Indoramin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of indoramin and monoamine oxidase inhibitors. This combination is listed as a contraindication in indoramin product labeling.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> Indoramin product labeling states that due to the risk of an enhanced hypotensive effect, the concomitant use of indoramin and monoamine oxidase (MAO) inhibitors is contradindicated.<sup>1,2</sup> Although not specifically stated in the product labels, this contraindication is likely directed at MAO inhibitors used in the treatment of depression (ie, phenelzine, tranylcypromine, and isocarboxazid) since their use has been associated with the greatest incidence of hypotension.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Doralese Tiltab (indoramin) [summary of product characteristics]. Surrey, UK: Chemidex Pharmac Ltd; November 2015.</p>\n<p>2. Baratol (indoramin) [summary of product characteristics]. London, UK: Concordia International; December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10740":"<p><b>Title</b> Ceritinib / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease the serum concentration of Ceritinib. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of healthy subjects, esomeprazole (40 mg daily x 6 days) decreased the ceritinib (750 mg single dose) AUC and maximum serum concentration (Cmax) 76% and 79%, respectively.<sup>1,2</sup> <br><br>However, a subgroup analysis of a clinical trial of patients with non-small cell lung cancer found that use of a proton pump inhibitor (PPI) (defined as use of a PPI for at least 5 consecutive days prior to ceritinib therapy) resulted in a ceritinib (750 mg single dose) AUC and Cmax that were only 30% and 25% lower, respectively, than those of patients who had not taken a PPI.<sup>1,2</sup> And, after daily dosing of ceritinib, PPIs had no clinically significant effect on ceritinib exposure.<sup>1,2</sup> In another pooled subgroup analysis of patients from 3 clinical trials, patients who took a PPI (defined as use of a PPI for at least 70% of the time ceritinib therapy was administered) had similar ceritinib trough concentrations and similar overall response rates compared with patients who had not taken a PPI.<sup>1</sup><br><br>The mechanism of this interaction is likely due to the pH-dependent solubility of ceritinib, which in vitro, has been shown to become poorly soluble as pH increases.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lau YY, Gu W, Lin T, et al. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer. <i>Cancer Chemother Pharmacol</i>. 2017;79(6):1119-1128. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28424965\">[PubMed 28424965]</a></p>\n<p>2. Zykadia (ceritinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; September 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10741":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inducers) / Glycerol Phenylbutyrate</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Glycerol Phenylbutyrate may decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action is required for the majority of CYP3A4 substrates. Monitoring for decreased therapeutic effects for substrates with a narrow therapeutic index (eg, alfentanil, quinidine, cyclosporine, midazolam) may be warranted.</p>\n<div>\n <p><b>CYP3A4 Substrates (High risk with Inducers) Interacting Members</b> Abemaciclib, Abiraterone Acetate, Acalabrutinib, Alfuzosin, ALPRAZolam, Amiodarone, AmLODIPine, Apixaban, Apremilast, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Armodafinil, Artemether, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Bedaquiline, Benidipine, Benzhydrocodone, Benzphetamine, Bisoprolol, Blonanserin, Boceprevir, Bortezomib, Bosutinib, Brexpiprazole, Brigatinib, Bromperidol, Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Citalopram, Clarithromycin, ClonazePAM, Clorazepate, Cobicistat, Cobimetinib, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Daclatasvir, Dantrolene, Dapsone (Systemic), Darifenacin, Darunavir, Dasabuvir, Dasatinib, Deflazacort, Delavirdine, Dexamethasone (Systemic), DiazePAM, Dienogest, Digitoxin, DilTIAZem, Disopyramide, DOCEtaxel, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Efavirenz, Elbasvir, Eliglustat, Elvitegravir, Enzalutamide, Eplerenone, Erlotinib, Erythromycin (Systemic), Escitalopram, Estradiol (Systemic), Estradiol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Eszopiclone, Ethinyl Estradiol, Ethosuximide, Etizolam, Etoposide, Etoposide Phosphate, Etoricoxib, Etravirine, Everolimus, Exemestane, Felbamate, Felodipine, Fesoterodine, Flibanserin, Flurazepam, Fosamprenavir, Fosaprepitant, Gefitinib, Gemigliptin, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Idelalisib, Imatinib, Indinavir, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ixazomib, Ketoconazole (Systemic), Lacidipine, Lansoprazole, Lapatinib, Lercanidipine, Levonorgestrel (Systemic), Lidocaine (Systemic), Linagliptin, Lomitapide, Losartan, Lovastatin, Lumefantrine, Lurasidone, Lynestrenol, Macimorelin, Macitentan, Manidipine, Maraviroc, MedroxyPROGESTERone, Mefloquine, Mestranol, Methadone, Mianserin, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Modafinil, Naldemedine, Naloxegol, Nefazodone, Nelfinavir, Neratinib, Netupitant, Nevirapine, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Norethindrone, Norgestrel, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Ondansetron, Osimertinib, Ospemifene, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Perampanel, Pimozide, Piperaquine, Pipotiazine, Praziquantel, Primaquine, Progesterone, QUEtiapine, QuiNIDine, QuiNINE, RABEprazole, Radotinib, Ranolazine, Regorafenib, Repaglinide, Ribociclib, Rifabutin, Rilpivirine, Riociguat, Ritonavir, Rivaroxaban, Roflumilast, Rolapitant, RomiDEPsin, Saquinavir, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tamoxifen, Tamsulosin, Tasimelteon, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tetracycline (Systemic), Tezacaftor, TiaGABine, Tibolone, Ticagrelor, Ticlopidine, Tipranavir, Tofacitinib, Tolterodine, Tolvaptan, Toremifene, Trabectedin, TraMADol, TraZODone, Triazolam, Trimethoprim, Trimipramine, Ulipristal, Valbenazine, Vandetanib, Velpatasvir, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, Vilazodone, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vortioxetine, Voxilaprevir, Zolpidem, Zonisamide, Zopiclone</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the glycerol phenylbutyrate prescribing information, glycerol phenylbutyrate (4 mL three times daily x 3 days) decreased the CYP3A4 substrate midazolam AUC and maximum serum concentration (Cmax) 32% and 25%, respectively.<sup>1</sup> The AUC and Cmax of the 1-hydroxy midazolam metabolite increased 58% and 28%, respectively.<sup>1</sup><br><br>The mechanism of this interaction is likely due to glycerol phenylbutyrate induction of CYP3A4, the enzyme responsible for midazolam metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Raviciti (glycerol phenylbutyrate) [prescribing information]. Lake Forest, IL: Horizon Pharma USA Inc; September 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10742":"<p><b>Title</b> Digoxin / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of Digoxin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Reduce the digoxin dose by approximately 30% to 50%, or reduce the dosing frequency, when these agents are combined. Monitor digoxin levels closely and adjust digoxin dose as needed.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, ritonavir (300 mg twice daily x 11 days) increased the digoxin (0.5 mg single dose) AUC 86% and prolonged the half-life 156%.<sup>1</sup> In another pharmacokinetic study, ritonavir (400 mg twice daily x 14 days) increased the digoxin (0.5 mg single dose) AUC 37%.<sup>2</sup> In other analyses, the use of darunavir/ritonavir (600 mg/100 mg twice daily), lopinavir/ritonavir (400 mg/100 mg twice daily), and saquinavir/ritonavir (1,000 mg/100 mg twice daily) increased the digoxin AUC 36%, 81%, and 49%, respectively.<sup>3,4,5</sup> In support of these studies, 2 case reports describe patients who experienced elevated digoxin serum concentrations and toxicities after the addition of ritonavir therapy.<sup>6,7</sup><br><br>Digoxin prescribing information states that because ritonavir can significantly elevate digoxin concentrations, the digoxin dose should be reduced 30% to 50%, or the dosing frequency should be reduced, if combined with ritonavir.<sup>8</sup><br> <br>The mechanism of this interaction is likely due to ritonavir-mediated P-glycoprotein inhibition, a transporter responsible for digoxin disposition.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ding R, Tayrouz Y, Riedel KD, et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. <i>Clin Pharmacol Ther</i>. 2004;76(1):73-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15229466\">[PubMed 15229466]</a></p>\n<p>2. Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, Unadkat JD. Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion. <i>Drug Metab Dispos</i>. 2012;40(3):610-616. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22190694\">[PubMed 22190694]</a></p>\n<p>3. Prezista (darunavir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; June 2016.</p>\n<p>4. Wyen C, Fuhr U, Frank D, et al. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. <i>Clin Pharmacol Ther</i>. 2008;84(1):75-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18183034\">[PubMed 18183034]</a></p>\n<p>5. Schmitt C, Kaeser B, Riek M, Bech N, Kreuzer C. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. <i>Int J Clin Pharmacol Ther</i>. 2010;48(3):192-199. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20197013\">[PubMed 20197013]</a></p>\n<p>6. Phillips EJ, Rachlis AR, Ito S. Digoxin toxicity and ritonavir: a drug interaction mediated through p-glycoprotein? <i>AIDS</i>. 2003;17(10):1577-1578. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12824804\">[PubMed 12824804]</a></p>\n<p>7. Yoganathan K, Roberts B, Heatley MK. Life-threatening digoxin toxicity due to drug-drug interactions in an HIV-positive man [published online July 19, 2016]. <i>Int J STD AIDS</i>. doi: 10.1177/0956462416661437. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27440872\">[PubMed 27440872]</a></p>\n<p>8. Digoxin [prescribing information]. Columbus, OH: Roxane Laboratories Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10743":"<p><b>Title</b> MetFORMIN / Isavuconazonium Sulfate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Isavuconazonium Sulfate may increase the serum concentration of MetFORMIN. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased metformin effects/toxicities when combined with isavuconazonium.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 20 healthy volunteers, isavuconazonium (200 mg three times daily x 2 days, followed by 200 mg daily x 5 days) increased the metformin (850 mg single dose) AUC and maximum serum concentration 52% and 23%, respectively.<sup>1</sup><br><br>The mechanism of this potential interaction has not been fully investigated, but isavuconazonium inhibition of OCT1, OCT2, and/or MATE1, transporters involved in metformin elimination, likely contributes.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Yamazaki T, Desai A, Goldwater R, et al. Pharmacokinetic interactions between isavuconazole and the drug transporter substrates atorvastatin, digoxin, metformin, and methotrexate in healthy subjects. [published online June 8, 2016]. <i>Clin Pharmacol Drug Dev</i>. doi: 10.1002/cpdd.280. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27273004\">[PubMed 27273004]</a></p>\n<p>2. Cresemba (isavuconazonium sulfate) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10744":"<p><b>Title</b> Methadone / Isavuconazonium Sulfate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Isavuconazonium Sulfate may decrease the serum concentration of Methadone. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased methadone effects/withdrawal symptoms if combined with isavuconazonium.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 22 healthy volunteers, the concomitant administration of methadone (10 mg daily x 10 days) and isavuconazonium (200 mg three times daily x 2 days, followed by 200 mg daily x 10 days) decreased the R-methadone AUC 10% and decreased the S-methadone AUC 35%.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is isavuconazole (from isavuconazonium sulfate) induction of CYP2B6-mediated methadone metabolism.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Yamazaki T, Desai A, Goldwater R, et al. Pharmacokinetic effects of isavuconazole coadministration with the cytochrome P450 enzyme substrates bupropion, repaglinide, caffeine, dextromethorphan, and methadone in healthy subjects [published online June 8, 2016]. <i>Clin Pharmacol Drug Dev</i>. doi: 10.1002/cpdd.281. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27273149\">[PubMed 27273149]</a></p>\n<p>2. Cresemba (isavuconazonium sulfate) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10745":"<p><b>Title</b> Antipsychotic Agents (Phenothiazines) / Chlorphenesin Carbamate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Chlorphenesin Carbamate may enhance the adverse/toxic effect of Antipsychotic Agents (Phenothiazines). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of increased effects of one or both of these drugs when using them in combination. Use caution with the combination, and consider a dose reduction in patients who may be at higher risk from any enhancement of drug effects.</p>\n<div>\n <p><b>Antipsychotic Agents (Phenothiazines) Interacting Members</b> ChlorproMAZINE, FluPHENAZine, Methotrimeprazine, Periciazine, Perphenazine, Pipotiazine, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine</p>\n</div> \n<p><b>Discussion</b> The chlorphenesin carbamate labeling states that concurrent use with phenothiazines, CNS depressants, monoamine oxidase inhibitors, or alcohol may result in a mutual increase in drug effects, recommending caution and a consideration of dose reduction.<sup>1</sup><br><br>The specific mechanism for such an effect is uncertain, but additive CNS depressant effects could be at least partially responsible for such an effect.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rinlaxer (chlorphenesin carbamate) [prescribing information]. Toshima, Tokyo, Japan: Taisho Pharmaceutical Co., Ltd.; July 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10746":"<p><b>Title</b> CNS Depressants / Chlorphenesin Carbamate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Chlorphenesin Carbamate may enhance the adverse/toxic effect of CNS Depressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of increased effects of one or both of these drugs when using them in combination. Use caution with the combination, and consider a dose reduction in patients who may be at higher risk from any enhancement of drug effects.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The chlorphenesin carbamate labeling states that concurrent use with phenothiazines, CNS depressants, monoamine oxidase inhibitors, or alcohol may result in a mutual increase in drug effects, recommending caution and a consideration of dose reduction.<sup>1</sup><br><br>The specific mechanism for such an effect is uncertain, but additive CNS depressant effects could be at least partially responsible for such an effect.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rinlaxer (chlorphenesin carbamate) [prescribing information]. Toshima, Tokyo, Japan: Taisho Pharmaceutical Co., Ltd.; July 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10747":"<p><b>Title</b> Monoamine Oxidase Inhibitors / Chlorphenesin Carbamate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Chlorphenesin Carbamate may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of increased effects of one or both of these drugs when using them in combination. Use caution with the combination, and consider a dose reduction in patients who may be at higher risk from any enhancement of drug effects.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> The chlorphenesin carbamate labeling states that concurrent use with phenothiazines, CNS depressants, monoamine oxidase inhibitors, or alcohol may result in a mutual increase in drug effects, recommending caution and a consideration of dose reduction.<sup>1</sup><br><br>The specific mechanism for such an effect is uncertain, but additive CNS depressant effects could be at least partially responsible for such an effect.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rinlaxer (chlorphenesin carbamate) [prescribing information]. Toshima, Tokyo, Japan: Taisho Pharmaceutical Co., Ltd.; July 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10748":"<p><b>Title</b> Chlorphenesin Carbamate / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of Chlorphenesin Carbamate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of increased effects of one or both of these drugs when using them in combination. Use caution with the combination, and consider a dose reduction in patients who may be at higher risk from any enhancement of drug effects.</p> \n<p><b>Discussion</b> The chlorphenesin carbamate labeling states that concurrent use with phenothiazines, CNS depressants, monoamine oxidase inhibitors, or alcohol may result in a mutual increase in drug effects, recommending caution and a consideration of dose reduction.<sup>1</sup><br><br>The specific mechanism for such an effect is uncertain, but additive CNS depressant effects could be at least partially responsible for such an effect.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rinlaxer (chlorphenesin carbamate) [prescribing information]. Toshima, Tokyo, Japan: Taisho Pharmaceutical Co., Ltd.; July 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10749":"<p><b>Title</b> Loperamide-Loperamide Oxide / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Loperamide-Loperamide Oxide. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action necessary with use of normal doses of these drugs in most patients. Advise patients to avoid use of excessive doses of either drug, particularly in combination, and to promptly report any evidence of possible toxicity including any evidence of arrhythmia. Patients with other risk factors for QT prolongation or ventricular arrhythmias may be at particular risk with such a combination.</p>\n<div>\n <p><b>Loperamide-Loperamide Oxide Interacting Members</b> Loperamide, Loperamide Oxide</p>\n</div> \n<p><b>Discussion</b> The US FDA released a warning about serious, potentially fatal heart problems that may be associated with the use of high doses of loperamide.<sup>1</sup> A part of this warning focused on potential drug interactions that may further increase the risk for serious toxicities when combined with loperamide, and cimetidine is listed as a drug that may interact with loperamide. Specific data about this combination are not available, but cimetidine is a weak inhibitor of CYP3A4 at clinically relevant doses,<sup>2,3,4</sup> and CYP3A4 has been shown to be partially responsible for loperamide metabolism,<sup>5</sup> suggesting that cimetidine may somewhat impair loperamide metabolism, leading to increased concentrations and effects of loperamide.</p> \n<p><b>Footnotes</b> </p>\n<p>1. U.S. Food and Drug Administration. Loperamide (Imodium): Drug Safety Communication - Serious Heart Problems With High Doses From Abuse and Misuse. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm505303.htm (accessed 6/9/2016).</p>\n<p>2. Boffito M, Carriero P, Trentini L, et al. Pharmacokinetics of saquinavir co-administered with cimetidine. <i>J Antimicrob Chemother</i>. 2002;50(6):1081-1084. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12461038\">[PubMed 12461038]</a></p>\n<p>3. Wilner K, Laboy L, LeBel M. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. <i>Br J Clin Pharmacol</i>. 2002;53 Suppl 1:31S-36S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11879257\">[PubMed 11879257]</a></p>\n<p>4. Martinez C, Albet C, Agundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. <i>Clin Pharmacol Ther</i>. 1999;65(4):369-376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10223772\">[PubMed 10223772]</a></p>\n<p>5. Kim KA, Chung J, Jung DH, Park JY. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. <i>Eur J Clin Pharmacol</i>. 2004;60(8):575-581. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15365656\">[PubMed 15365656]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10750":"<p><b>Title</b> Loperamide-Loperamide Oxide / CYP2C8 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (CYP3A4 Inhibitors (Strong)): The significance of this interaction may be greater with concurrent use of a strong CYP3A4 inhibitor. Consider avoiding loperamide use (especially regular or high-dose) with both a strong CYP2C8 and strong CYP3A4 inhibitor.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP2C8 Inhibitors (Strong) may increase the serum concentration of Loperamide-Loperamide Oxide. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action necessary with use of normal doses of these drugs in most patients. Advise patients to avoid use of excessive doses of either drug, particularly in combination, and to promptly report any evidence of possible toxicity including any evidence of arrhythmia. Patients with other risk factors for QT prolongation or ventricular arrhythmias may be at particular risk with such a combination.</p>\n<div>\n <p><b>CYP2C8 Inhibitors (Strong) Interacting Members</b> Gemfibrozil</p>\n <p><b>Loperamide-Loperamide Oxide Interacting Members</b> Loperamide, Loperamide Oxide</p>\n</div> \n<p><b>Discussion</b> In a well controlled study involving 12 healthy volunteers, gemfibrozil (600 mg twice daily for 5 days) increased Cmax and AUC of single-dose loperamide (4 mg given on day 3 of gemfibrozil) by 1.6-fold and 2.2-fold, respectively compared to placebo.<sup>1</sup> The gemfibrozil-associated increase in loperamide concentration was not associated with an increase in loperamide-related psychomotor effects (drowsiness, Digit Symbol Substitution Test (DSST) score).<br><br>A safety communication released by the FDA describes serious cardiac arrhythmias included torsades de pointes (TdP), primarily in individuals taking very high doses of loperamide in misuse/abuse situations.<sup>2</sup> In some of these instances, patients were purposefully taking other drugs with loperamide to further increase loperamide concentration and loperamide-related effects (eg, euphoria). In other instances, the report states that patients were taking the recommended dose of loperamide with concurrent interacting medicines. The drugs implicated in increased loperamide concentrations resulting in cardiac TdP were not identified in the report.<br><br>CYP2C8 has been shown to be partially responsible for loperamide metabolism,<sup>3</sup> suggesting that strong CYP2C8 inhibitors such as gemfibrozil may at least somewhat impair loperamide metabolism, leading to increased concentrations and effects of loperamide. CYP3A4 also appears significant for loperamide metabolism, as the combination of itraconazole (a strong CYP3A4 inhibitor) with the CYP2C8 inhibitor gemfibrozil was associated with a 12.6-fold increase in loperamide AUC, a substantially greater impact than the respective 3.8- and 2.2-fold increases observed with itraconazole and gemfibrozil alone.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Niemi M, Tornio A, Pasanen MK, Fredrikson H, Neuvonen PJ, Backman JT. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. <i>Eur J Clin Pharmacol</i>. 2006;62(6):463-472. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16758263\">[PubMed 16758263]</a></p>\n<p>2. U.S. Food and Drug Administration. Loperamide (Imodium): Drug Safety Communication - Serious Heart Problems With High Doses From Abuse and Misuse. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm505303.htm (accessed 6/9/2016).</p>\n<p>3. Kim KA, Chung J, Jung DH, Park JY. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. <i>Eur J Clin Pharmacol</i>. 2004;60(8):575-581. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15365656\">[PubMed 15365656]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10751":"<p><b>Title</b> Loperamide-Loperamide Oxide / CYP3A4 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (CYP2C8 Inhibitors (Strong)): The significance of this interaction may be greater with concurrent use of a strong CYP2C8 inhibitor. Consider avoiding loperamide use (especially regular or high-dose) with both a strong CYP2C8 and strong CYP3A4 inhibitor.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Loperamide-Loperamide Oxide. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action necessary with use of normal doses of these drugs in most patients. Advise patients to avoid use of excessive doses of either drug, particularly in combination, and to promptly report any evidence of possible toxicity including any evidence of arrhythmia. Patients with other risk factors for QT prolongation or ventricular arrhythmias may be at particular risk with such a combination.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n <p><b>Loperamide-Loperamide Oxide Interacting Members</b> Loperamide, Loperamide Oxide</p>\n</div> \n<p><b>Discussion</b> Coadministration of loperamide with all strong CYP3A4 inhibitors has not been specifically evaluated. However, data with the strong CYP3A4 inhibitors itraconazole, ritonavir, and saquinavir indicate a substantial increase in loperamide exposure is possible. In one controlled study of 12 healthy volunteers, itraconazole (100 mg twice daily for 5 days) increased Cmax and AUC of single-dose loperamide (4 mg given on day 3 of itraconazole) by 2.9-fold and 3.8-fold, respectively, compared to placebo.<sup>1</sup> The half-life of loperamide increased from 11.9 hours to 18.7 hours indicating accumulation may occur with repeated dosing. In a similar trial of 11 volunteers, ritonavir (200 mg twice daily for 6 days) increased the Cmax and AUC of single-dose loperamide (16 mg given on day 6 of ritonavir) by 1.8-fold and 2.2-fold respectively.<sup>2</sup> In a single-dose study involving 12 healthy volunteers, ritonavir (600 mg) increased the Cmax and AUC of single dose loperamide 16 mg by 1.2-fold and 3.2-fold, respectively compared to placebo.<sup>3</sup> Ritonavir did not prolong the half-life of loperamide. The loperamide Cmax and AUC were an average of 1.2- and 1.4-fold higher, respectively, with concurrent saquinavir in a study of 12 healthy volunteers who received a single dose of loperamide (16 mg) with or without saquinavir (600 mg).<sup>4</sup> Despite the increases in loperamide exposure in each of these studies, none of the studies reported significant increases in measures of central opioid effects (eg, pupil diameter, pain threshold/tolerance, C0<sub>2</sub> sensitivity, etc.), QT interval, or occurrence of torsades de pointes (TdP) or other arrhythmias.<br><br>A safety communication released by the FDA describes serious cardiac arrhythmias included torsades de pointes (TdP), primarily in individuals taking very high doses of loperamide in misuse/abuse situations.<sup>5</sup> In some of these instances, patients were purposefully taking other drugs with loperamide to further increase loperamide concentration and loperamide-related effects (eg, euphoria). In other instances, the report states that patients were taking the recommended dose of loperamide with concurrent interacting medicines. The drugs implicated in increased loperamide concentrations resulting in cardiac TdP were not identified in the report.<br><br>CYP3A4 has been shown to be partially responsible for loperamide metabolism,<sup>6</sup> suggesting that strong CYP3A4 inhibitors such as itraconazole or ritonavir may at least somewhat impair loperamide metabolism, leading to increased concentrations and effects of loperamide. CYP2C8 also appears significant for loperamide metabolism,<sup>6</sup> and the combination of itraconazole (a strong CYP3A4 inhibitor) with the CYP2C8 inhibitor gemfibrozil was associated with a 12.6-fold increase in loperamide AUC, a substantially greater impact than the respective 3.8- and 2.2-fold increases observed with itraconazole and gemfibrozil alone.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Niemi M, Tornio A, Pasanen MK, Fredrikson H, Neuvonen PJ, Backman JT. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. <i>Eur J Clin Pharmacol</i>. 2006;62(6):463-472. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16758263\">[PubMed 16758263]</a></p>\n<p>2. Mukwaya G, MacGregor T, Hoelscher D, et al. Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. <i>Antimicrob Agents Chemother</i>. 2005;49(12):4903-4910. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16304151\">[PubMed 16304151]</a></p>\n<p>3. Tayrouz Y, Ganssmann B, Ding R, et al. Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. <i>Clin Pharmacol Ther</i>. 2001;70(5):405-414. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11719726\">[PubMed 11719726]</a></p>\n<p>4. Mikus G, Schmidt L, Burhenne J, et al. Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction. <i>Clin Pharmacokinet</i>. 2004;43(14):1015-1024. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15530130\">[PubMed 15530130]</a></p>\n<p>5. U.S. Food and Drug Administration. Loperamide (Imodium): Drug Safety Communication - Serious Heart Problems With High Doses From Abuse and Misuse. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm505303.htm (accessed 6/9/2016).</p>\n<p>6. Kim KA, Chung J, Jung DH, Park JY. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. <i>Eur J Clin Pharmacol</i>. 2004;60(8):575-581. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15365656\">[PubMed 15365656]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10752":"<p><b>Title</b> Desmopressin / Loperamide-Loperamide Oxide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Loperamide-Loperamide Oxide may increase the serum concentration of Desmopressin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor closely for evidence of increased desmopressin effects when using these drugs in combination.</p>\n<div>\n <p><b>Loperamide-Loperamide Oxide Interacting Members</b> Loperamide, Loperamide Oxide</p>\n</div> \n<p><b>Discussion</b> The desmopressin AUC was an average of 3.1-fold higher in a study of 18 subjects who received a dose of desmopressin 400 mcg orally with loperamide 4 mg administered 24 hours, 12 hours, and 1 hour before the desmopressin.<sup>1</sup> The clinical significance of this interaction is unclear.<br><br>The specific mechanism for such an effect is uncertain, but increased absorption of desmopressin due to the slower GI motility caused by loperamide is one suggested mechanism.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Callreus T, Lundahl J, Hoglund P, Bengtsson P. Changes in gastrointestinal motility influence the absorption of desmopressin. <i>Eur J Clin Pharmacol</i>. 1999;55(4):305-309. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10424324\">[PubMed 10424324]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10753":"<p><b>Title</b> Eluxadoline / Loperamide-Loperamide Oxide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Loperamide-Loperamide Oxide may enhance the constipating effect of Eluxadoline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Loperamide may be used used occasionally to treat diarrhea in patients being treated with eluxadoline, but chronic or regular use of loperamide should be avoided. Discontinue loperamide promptly if constipation occurs.</p>\n<div>\n <p><b>Loperamide-Loperamide Oxide Interacting Members</b> Loperamide, Loperamide Oxide</p>\n</div> \n<p><b>Discussion</b> According to the eluxadoline prescribing information, chronic use of loperamide with eluxadoline should be avoided, but occasional use of loperamide is permitted.<sup>1</sup> Patients should immediately discontinue loperamide if constipation occurs.<br><br>Both drugs work on opioid receptors in the gastrointestinal tract to slow motility, suggesting that their combined use could cause additive or synergistic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viberzi (eluxadoline) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals, Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10754":"<p><b>Title</b> Ramosetron / Loperamide-Loperamide Oxide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Loperamide-Loperamide Oxide may enhance the constipating effect of Ramosetron. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients receiving ramosetron in combination with loperamide for an increased risk of constipation.</p>\n<div>\n <p><b>Loperamide-Loperamide Oxide Interacting Members</b> Loperamide, Loperamide Oxide</p>\n</div> \n<p><b>Discussion</b> Ramosetron Korean product labeling states that its use in combination with loperamide may increase the risk of adverse effects including constipation.<sup>1</sup> This interaction is anticipated based on the independent constipating effects of ramosetron and loperamide.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Irribow (ramosetron) tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200905270. Accessed June 17, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10755":"<p><b>Title</b> Loperamide-Loperamide Oxide / RaNITIdine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> RaNITIdine may enhance the arrhythmogenic effect of Loperamide-Loperamide Oxide. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action necessary with use of normal doses of these drugs in most patients. Advise patients to avoid use of excessive doses of either drug, particularly in combination, and to promptly report any evidence of possible toxicity including any evidence of arrhythmia. Patients with other risk factors for QT prolongation or ventricular arrhythmias may be at particular risk with such a combination.</p>\n<div>\n <p><b>Loperamide-Loperamide Oxide Interacting Members</b> Loperamide, Loperamide Oxide</p>\n</div> \n<p><b>Discussion</b> The US FDA released a warning about serious, potentially fatal heart problems that may be associated with the use of high doses of loperamide.<sup>1</sup> A part of this warning focused on potential drug interactions that may further increase the risk for serious toxicities when combined with loperamide, and ranitidine is listed as a drug that may interact with loperamide. Specific data about this combination are not available, and the likely mechanism for this interaction is unknown. Ranitidine is not expected to increase loperamide concentrations or alter its distribution, and ranitidine has not been closely associated with proarrhythmic effects of its own.</p> \n<p><b>Footnotes</b> </p>\n<p>1. U.S. Food and Drug Administration. Loperamide (Imodium): Drug Safety Communication - Serious Heart Problems With High Doses From Abuse and Misuse. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm505303.htm (accessed 6/9/2016).</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10756":"<p><b>Title</b> DOCEtaxel / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of DOCEtaxel. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of docetaxel and strong CYP3A4 inhibitors when possible. If combined use is unavoidable, consider a 50% docetaxel dose reduction and monitor for increased docetaxel toxicities.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In 2 crossover studies, the concomitant use of docetaxel (10 mg/m<sup>2</sup> to 15 mg/m<sup>2</sup>) and oral ketoconazole (200 mg to 1,200 mg per day) reduced docetaxel clearance by approximately 50% compared with administration of docetaxel (100 mg/m<sup>2</sup>) alone.<sup>1,2</sup> One dose finding study found that ketoconazole 600 mg/day, 800 mg/day, and 1,200 mg/day increased the AUC of docetaxel (5 mg/m<sup>2</sup> to 43 mg/m<sup>2</sup>) 1.7-fold, 1.6-fold, and 2.6-fold, respectively.<sup>3</sup> In another study, docetaxel clearance was 40% lower in 31 patients who received docetaxel (70 mg flat dose) combined with ketoconazole (200 mg twice daily for 3 days) compared with 55 patients who received docetaxel (75 mg/m<sup>2</sup>) alone.<sup>4</sup> The combination of ketoconazole (200 mg twice daily for 3 days) and docetaxel decreased docetaxel clearance by 70% compared with that of historical controls who received docetaxel alone.<sup>5</sup> A retrospective cohort study found that the risk of developing grade 4 neutropenia was significantly higher among patients who received the combination of clarithromycin and docetaxel compared to those who received docetaxel alone (odds ratio 4.98; 95% CI [1.66 to 15.0]).<sup>6</sup> In support of these studies, case reports describe patients who experienced severe neutropenia and mucositis with the combination of docetaxel and ritonavir,<sup>7,8</sup> and this drug interaction has been used intentionally by using ritonavir to boost the systemic bioavailability of orally administered docetaxel.<sup>9,10</sup><br><br>In contrast, one study found that ketoconazole had no consistent effect on docetaxel pharmacokinetics.<sup>11</sup><br><br>Docetaxel prescribing information states that the use of docetaxel and strong CYP3A4 inhibitors should be avoided, but if coadministration is unavoidable, a 50% docetaxel dose reduction should be considered.<sup>12</sup><br><br>The mechanism of this interaction is likely due to inhibition of CYP3A4-mediated docetaxel metabolism. Inhibition of P-glycoprotein may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Engels FK, Ten Tije AJ, Baker SD, et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. <i>Clin Pharmacol Ther</i>. 2004;75(5):448-454. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15116057\">[PubMed 15116057]</a></p>\n<p>2. Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J. Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel. <i>Cancer Biol Ther</i>. 2006;5(7):833-839. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16775418\">[PubMed 16775418]</a></p>\n<p>3. Figg WD, Woo S, Zhu W, et al. A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. <i>J Urol</i>. 2010;183(6):2219-2226. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20399458\">[PubMed 20399458]</a></p>\n<p>4. Lim YW, Goh BC, Wang LZ, et al. Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients. <i>Ann Oncol</i>. 2010;21(11):2175-2182. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20430905\">[PubMed 20430905]</a></p>\n<p>5. Yong WP, Wang LZ, Tham LS, et al. A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers. <i>Cancer Chemother Pharmacol</i>. 2008;62(2):243-251. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17909805\">[PubMed 17909805]</a></p>\n<p>6. Tsuji D, Kamezato M, Daimon T, et al. Retrospective analysis of severe neutropenia in patients receiving concomitant administration of docetaxel and clarithromycin. <i>Chemotherapy</i>. 2013;59(6):407-413. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25011542\">[PubMed 25011542]</a></p>\n<p>7. Mir O, Dessard-Diana B, Lillo-Le Louet A, et al. Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients. <i>Br J Clin Pharmacol</i>. 2010; 69(1): 99-101. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20078618\">[PubMed 20078618]</a></p>\n<p>8. Loulergue P, Mir O, Allali J, Viard JP. Possible pharmacokinetic interaction involving ritonavir and docetaxel in a patient with Kaposi's sarcoma. <i>AIDS</i>. 2008;22(10):1237-1239. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18525276\">[PubMed 18525276]</a></p>\n<p>9. Oostendorp R, Huitema A, Rosing H, et al. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. <i>Clin Cancer Res</i>. 2009;15(12):4228-4233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19509162\">[PubMed 19509162]</a></p>\n<p>10. Moes JJ, Stuurman FE, Hendrikx JJ, et al. Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet. <i>Drug Deliv Transl Res</i>. 2013;3(3):243-251. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25788133\">[PubMed 25788133]</a></p>\n<p>11. Van Veldhuizen PJ, Reed G, Aggarwal A, Baranda J, Zulfiqar M, Williamson S. Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study. <i>Cancer</i>. 2003;98(9):1855-1862. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14584067\">[PubMed 14584067]</a></p>\n<p>12. Taxotere (docetaxel) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; December 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10757":"<p><b>Title</b> Velpatasvir / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ritonavir may decrease the serum concentration of Velpatasvir. Ritonavir may increase the serum concentration of Velpatasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent administration of sofosbuvir and velpatasvir with moderate or strong inducers of CYP2B6, such as ritonavir, is not recommended. Concurrent use of tipranavir/ritonavir is specifically not recommended, but the concurrent use of atazanavir/ritonavir or darunavir/ritonavir are permitted and described as having no significant interaction. Consider alternatives to ritonavir when possible, but monitor therapy closely if the combination must be used.</p> \n<p><b>Discussion</b> The velpatasvir AUC was an average of 82% lower with concurrent use of rifampin (600 mg/day), which is a strong inducer of CYP3A4, CYP2C8, CYP2B6, and p-glycoprotein.<sup>1,2</sup><br><br>The velpatasvir AUC was an average of 16% lower with concurrent darunavir/ritonavir (800 mg/100 mg daily), 2% higher with concurrent lopinavir/ritonavir (800 mg/200 mg daily), and 2.4-fold higher with concurrent atazanavir/ritonavir (300 mg/100 mg daily) according to studies of boosting doses of ritonavir in the sofosbuvir and velpatasvir labeling.<sup>1</sup><br><br>CYP3A4, CYP2C8, CYP2B6, and p-glycoprotein all appear to participate in velpatasvir disposition and metabolism,<sup>1,2</sup> and induction of one or more of these pathways would likely decrease velpatasvir concentrations to a potentially significant degree. Ritonavir is a moderate CYP2B6 inducer that also acts as a strong CYP3A4 inhibitor and an inhibitor of p-glycoprotein, making its net impact on velpatasvir concentrations difficult to predict.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; June 2016.</p>\n<p>2. Mogalian E, German P, Kearney BP, et al. Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir. <i>Clin Pharmacokinet</i>. 2016;55(5):605-613. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26519191\">[PubMed 26519191]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10758":"<p><b>Title</b> HydrOXYzine / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of HydrOXYzine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider alternatives to hydroxyzine when possible. This combination is specifically contraindicated in some non-U.S. labeling.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The Canadian labeling for hydroxyzine specifically contraindicates use with CYP3A4 inhibitors due to the risk for QT prolongation and possible Torsades de Pointes (TdP).<sup>1</sup> A published letter similarly describes changes recommended by the European Medicines Agency (EMA) to decrease the recommended doses for hydroxyzine that was also related to TdP concerns.<sup>2</sup> According to the letter, there may be up to 184 reported cases of TdP associated with hydroxyzine.<br><br>This warning appears to be related to a concern that CYP3A4 inhibitors may increase hydroxyzine concentrations, leading to an increased risk of toxicity. It is unclear exactly what role CYP3A4 has in hydroxyzine metabolism, and no studies could be found concerning the impact of CYP3A4 inhibitors on hydroxyzine concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Atarax (hydroxyzine) [product monograph]. Montreal, Quebec, Canada: ERFA Canada 2012 Inc.; May 2016.</p>\n<p>2. Mistraletti G, Iapichino G. Hydroxyzine and QTc interval: drugs without sin cast the first stone! <i>Minerva Anestesiol</i>. 2016;82(2):240-241. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26375793\">[PubMed 26375793]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10759":"<p><b>Title</b> HydrOXYzine / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HydrOXYzine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider alternatives to hydroxyzine when possible. This combination is specifically contraindicated in some non-U.S. labeling.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> The Canadian labeling for hydroxyzine specifically contraindicates use with CYP3A4 inhibitors due to the risk for QT prolongation and possible Torsades de Pointes (TdP).<sup>1</sup> A published letter similarly describes changes recommended by the European Medicines Agency (EMA) to decrease the recommended doses for hydroxyzine that was also related to TdP concerns.<sup>2</sup> According to the letter, there may be up to 184 reported cases of TdP associated with hydroxyzine.<br><br>This warning appears to be related to a concern that CYP3A4 inhibitors may increase hydroxyzine concentrations, leading to an increased risk of toxicity. It is unclear exactly what role CYP3A4 has in hydroxyzine metabolism, and no studies could be found concerning the impact of CYP3A4 inhibitors on hydroxyzine concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Atarax (hydroxyzine) [product monograph]. Montreal, Quebec, Canada: ERFA Canada 2012 Inc.; May 2016.</p>\n<p>2. Mistraletti G, Iapichino G. Hydroxyzine and QTc interval: drugs without sin cast the first stone! <i>Minerva Anestesiol</i>. 2016;82(2):240-241. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26375793\">[PubMed 26375793]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10760":"<p><b>Title</b> Azelastine (Systemic) / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Azelastine (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased azelastine adverse effects when used together with cimetidine.</p> \n<p><b>Discussion</b> According to the azelastine labeling, concurrent use of oral azelastine (4 mg twice daily) with cimetidine (400 mg twice daily) was associated with an average increase in azelastine concentrations of approximately 65%.<sup>1</sup> The clinical significance of this is unclear.<br><br>Several cytochrome P450 enzymes appear to participate in azelastine metabolism, suggesting that cimetidine, which is a weak or moderate inhibitor of several different cytochrome P450 enzymes, may increase azelastine concentrations by inhibiting its metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Astelin (azelastine) nasal spray [prescribing information]. Somerset, NJ: MEDA Pharmaceuticals Inc.; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10761":"<p><b>Title</b> Azelastine (Systemic) / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the sedative effect of Azelastine (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Caution patients that concurrent use of alcohol may enhance the sedative effects of azelastine.</p> \n<p><b>Discussion</b> According to the azelastine labeling, concurrent use of alcohol may increase the sedative effects of the azelastine.<sup>1</sup> Both azelastine and alcohol have been independently associated with sedation and other similar effects, so the combination could result in a significant additive or synergistic effect.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Azeptin (azelastine) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199001353. Accessed: April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10774":"<p><b>Title</b> Ramelteon / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Ramelteon. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased effects of ramelteon if used with a strong CYP3A4 inducer.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ramelteon prescribing information, the AUC of ramelteon (32 mg single dose) was decreased 80% when administered following an 11-day regimen of rifampin (600 mg daily).<sup>1</sup> Exposure to the M-II metabolite was similarly decreased.<sup>1</sup> <br><br>Ramelteon prescribing information states that concomitant use of ramelteon and strong CYP inducers may result in decreased ramelteon efficacy.<sup>1</sup><br><br>The mechanism of this potential interaction is likely due to rifampin induction of the CYP-mediated metabolism of ramelteon.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rozerem (ramelteon) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; November 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10775":"<p><b>Title</b> Riociguat / Enoximone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Enoximone may enhance the hypotensive effect of Riociguat. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of riociguat with nonselective phosphodiesterase inhibitors or phosphodiesterase type 5 inhibitors is contraindicated due to the risk of hypotension. While other phosphodiesterase inhibitors, such as enoximone, are not specifically contraindicated with riociguat, concomitant use should be undertaken with caution and patients should be monitored for the development of hypotension.</p> \n<p><b>Discussion</b> According to the riociguat prescribing information, use of single doses of riociguat (0.5 mg and 1 mg, sequential) in 7 patients with pulmonary arterial hypertension who were stable on the phosphodiesterase 5 (PDE5) inhibitor sildenafil (20 mg 3 times/day) was associated with additive hemodynamic effects.<sup>1</sup> Additionally, it is noted that among patients who received riociguat 1 to 2.5 mg 3 times/day together with sildenafil (20 mg 3 times/day) one death occurred that was deemed possibly related to the combination of riociguat and sildenafil.<sup>1</sup> A greater rate of drug discontinuation was also observed in patients receiving this combination. No clinical studies have been conducted with riociguat and other types of phosphodiesterase inhibitors so the combined effect on blood pressure is unknown.<br><br>Riociguat works by stimulating soluble guanylate cyclase, which is the receptor for nitric oxide, enhancing the production of cGMP. Similarly, phosphodiesterase inhibitors inhibit the breakdown of cyclic nucleotides that result in vasodilation such as cGMP or cAMP, resulting in possible additive or synergistic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Adempas (riociguat) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10776":"<p><b>Title</b> Anagrelide / Enoximone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Enoximone may enhance the adverse/toxic effect of Anagrelide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of anagrelide and enoximone.</p> \n<p><b>Discussion</b> Both enoximone and anagrelide are capable of inhibiting cyclic AMP phosphodiesterase III, so their combined use may result in additive or synergistic effects. Specific clinical data regarding this possible interaction are lacking, so this interaction potential remains theoretical at present, but anagrelide prescribing information states that their combined use should be avoided.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Agrylin (anagrelide) [prescribing information]. Wayne, PA: Shire US Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10777":"<p><b>Title</b> Meningococcal Group B Vaccine / Eculizumab</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Eculizumab may diminish the therapeutic effect of Meningococcal Group B Vaccine. Meningococcal Group B Vaccine may diminish the therapeutic effect of Eculizumab. The meningococcal vaccine may result in increased complement activation, possibly worsening the symptoms of any underlying complement-mediated diseases, such as hemolysis and anemia. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Non-U.S. labeling for eculizumab recommends that patients already being treated with eculizumab who require the meningococcal group B vaccine be vaccinated only when their disease is controlled and the concentrations of eculizumab in their blood are high. Since eculizumab is an immunosuppressant, it is recommended that all age-appropriate vaccinations (including meningococcal) be completed at least 2 weeks prior to initiation of eculizumab if possible, as reduced vaccine efficacy (eg, reduced immune response) may occur if administered to patients on immunosuppressant therapy. Prophylactic anti-meningococcal antibiotic therapy is recommended for patients who require initiation of eculizumab therapy sooner than 2 weeks after vaccination with the meningococcal group B vaccine.</p> \n<p><b>Discussion</b> A Health Canada safety review identified an increased risk of anemia or hemolysis among patients treated with eculizumab who were subsequently vaccinated with meningococcal group B vaccine.<sup>1</sup> According to this review, among users of the combination low hemoglobin was reported at a rate of approximately 1 case per month prior to receipt of the meningococcal group B vaccine but at a rate of approximately 16 cases per month in the 30 days following vaccination. The rate decreased again to less than 1 case per month beyond 30 days from the vaccination. The risk was highest among eculizumab-treated patients who received a dose of eculizumab within 2 weeks after receiving the meningococcal group B vaccine. The Canadian eculizumab labeling recommends that patients being treated with eculizumab should only receive the meningococcal group B vaccine when their disease is controlled and the eculizumab concentration in the blood is high.<sup>1,2</sup> It has been proposed that this increased risk for hemolysis and anemia results from further complement activation caused by the vaccine, resulting in a temporary worsening of the underlying complement-mediated disease.<sup>2</sup><br><br>General recommendations of the Advisory Committee on Immunization Practices (ACIP) state that inactivated vaccines, such as the meningococcal group B vaccine, can be administered safely to persons with altered immunocompetence.<sup>3</sup> The usual doses and schedules are recommended; however, the effectiveness of such vaccinations might be suboptimal.<sup>3</sup> If possible, all age-appropriate vaccinations should be completed at least 2 weeks prior to initiation of an immunosuppressant like eculizumab.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Health Canada Safety Review. Available at: http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/soliris-bexsero-eng.php. Accessed September 20, 2016.</p>\n<p>2. Soliris (eculizumab) [product monograph]. Zurich, Switzerland: Alexion Pharma GmbH; July 2016.</p>\n<p>3. National Center for Immunization and Respiratory Diseases. General recommendations on immunization - recommendations of the Advisory Committee on Immunization Practices (ACIP). [published correction appears in MMWR Recomm Rep. 2011;60(29):993]MMWR Recomm Rep. 2011;60(2):1-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21293327\">[PubMed 21293327]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10778":"<p><b>Title</b> Methadone / Lofexidine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Lofexidine may enhance the QTc-prolonging effect of Methadone. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concomitant use of lofexidine and methadone due to increased risk of QTc prolongation.</p> \n<p><b>Discussion</b> In a safety study of 14 adults with opioid dependence, the addition of lofexidine (titrated up to 1.6 mg daily over several weeks) to stable methadone therapy (80 mg daily x 3 weeks) increased the QTc interval a mean 21.9 msec compared with that of methadone treatment alone.<sup>1</sup> Two patients (14%) experienced a QTc increase of greater than 60 msec.<sup>1</sup> A case report describes one patient in the above study who, while stabilized on methadone (80 mg daily), experienced a QTc interval increase from 449 msec to 560 msec 4 hours after a single lofexidine dose (0.4 mg).<sup>2</sup> The QTc interval returned to 432 msec 24 hours later.<sup>2</sup><br><br>Lofexidine product labeling states that because there have been reports of QT prolongation during lofexidine treatment, concomitant use of drugs that prolong the QT interval (ie, methadone) should be avoided.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Schmittner J, Schroeder JR, Epstein DH, Krantz MJ, Eid NC, Preston KL. Electrocardiographic effects of lofexidine and methadone coadministration: secondary findings from a safety study. <i>Pharmacotherapy</i>. 2009;29(5):495-502. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19397459\">[PubMed 19397459]</a></p>\n<p>2. Schmittner J, Schroeder JR, Epstein DH, Preston KL. QT interval increased after single dose of lofexidine. <i>BMJ</i>. 2004;329(7474):1075. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15528619\">[PubMed 15528619]</a></p>\n<p>3. BritLofex (lofexidine) [summary of product characteristics]. Berkshire, UK: Britannia Pharmaceuticals; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10779":"<p><b>Title</b> CNS Depressants / Lofexidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Lofexidine may enhance the CNS depressant effect of CNS Depressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for enhanced sedation and CNS depression if lofexidine is combined with other CNS depressants.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> In a crossover comparison study of lofexidine and clonidine, lofexidine was found to have sedative effects similar to those of clonidine.<sup>1</sup> Lofexidine prescribing information states that drowsiness, sedation, and somnolence have been very commonly reported and that the concomitant use of lofexidine with CNS depressants may lead to enhanced CNS depression.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Dollery CT, Reid JL. Double-blind comparison of the hypotensive, sedative and salivary flow effects of lofexidine and clonidine in normal subjects. <i>Arzneimittelforschung</i>. 1982;32(8a):984-987. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6890374\">[PubMed 6890374]</a></p>\n<p>2. BritLofex (lofexidine) [summary of product characteristics]. Berkshire, UK: Britannia Pharmaceuticals; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10780":"<p><b>Title</b> Lurasidone / Atazanavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (Cobicistat): Use of atazanavir/cobicistat with lurasidone is contraindicated.</p></li>\n <li><p><b>Additional drug/group</b> (Ritonavir): Use of ritonavir-boosted atazanavir with lurasidone is contraindicated.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Atazanavir may increase the serum concentration of Lurasidone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Atazanavir labeling recommends reducing the lurasidone dose as directed by the lurasidone labeling for moderate CYP3A4 inhibitors when used together with lurasidone. Lurasidone U.S. labeling recommends reducing the lurasidone dose by half when used together with a moderate CYP3A4 inhibitor. Some non-U.S. labeling recommends initiating lurasidone at a dose of 20 mg/day and limiting lurasidone to 40 mg/day with concomitant use of moderate CYP3A4 inhibitors. Concurrent use of ritonavir-boosted atazanavir or atazanavir/cobicistat with lurasidone is contraindicated.</p> \n<p><b>Discussion</b> Coadministration of the moderate CYP3A4 inhibitor diltiazem (240 mg/day) increased lurasidone maximum concentration and AUC by approximately 2-fold each, respectively.<sup>1</sup> The likely primary mechanism of this interaction is diltiazem inhibition of CYP3A4-mediated lurasidone metabolism. The atazanavir labeling recommends reducing the lurasidone dose as recommended for moderate CYP3A4 inhibitors when used together with unboosted atazanavir.<sup>2</sup> Whether atazanavir is a moderate or strong CYP3A4 inhibitor is uncertain, as it has been shown to increase the AUC of the CYP3A4 substrate saquinavir by 5.5-fold, but the AUC of the substrate maraviroc was increased by only 3.6-fold.<sup>2,3</sup><br><br>Lurasidone U.S. prescribing information recommends reducing the lurasidone dose by half when used together with a moderate CYP3A4 inhibitor.<sup>1</sup> The lurasidone Canadian product monograph recommends initiating lurasidone at a dose of 20 mg/day and limiting lurasidone to 40 mg/day with concomitant use of moderate CYP3A4 inhibitors.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Latuda (lurasidone) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; July 2013.</p>\n<p>2. Reyataz (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; September 2016.</p>\n<p>3. Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. <i>Br J Clin Pharmacol</i>. 2008;65 Suppl 1:27-37. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18333863\">[PubMed 18333863]</a></p>\n<p>4. Latuda (lurasidone) [product monograph]. Mississauga, Ontario, Canada: Sunovion Pharmaceuticals Canada Inc.; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10781":"<p><b>Title</b> Meningococcal (Groups A / C / Y and W-135) Diphtheria Conjugate Vaccine / Diphtheria and Tetanus Toxoids, and Acellular Pertussis Vaccine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Age</b>: This interaction has only been described in patients 4 to 6 years old.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Diphtheria and Tetanus Toxoids, and Acellular Pertussis Vaccine may diminish the therapeutic effect of Meningococcal (Groups A / C / Y and W-135) Diphtheria Conjugate Vaccine. More specifically, prior administration of the diphtheria and tetanus toxoids, and acellular pertussis vaccine may diminish antibody response to the meningococcal (groups A / C / Y / and W-135) diphtheria conjugate vaccine in some patients. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer the meningococcal (groups A / C / Y and W-135) diphtheria conjugate vaccine (Menactra brand) before or concurrently with the diphtheria and tetanus toxoids, and acellular pertussis vaccine (Daptacel brand) in children 4 to 6 years of age.</p> \n<p><b>Discussion</b> US prescribing information states that the meningococcal (groups A / C / Y and W-135) diphtheria conjugate vaccine (Menactra brand) should be administered before or concurrently with the diphtheria and tetanus toxoids, and acellular pertussis vaccine (Daptacel brand) in children 4 to 6 years of age.<sup>1</sup> In a clinical study of children 4 to 6 years of age, administration of the diphtheria and tetanus toxoids, and acellular pertussis vaccine (in combination with inactivated polio vaccine) 30 days prior to the meningococcal vaccine was associated with lower serum bactericidal-complement titers to all meningococcal strains 30 days after vaccine administration, when compared with administration of the meningococcal vaccine (and inactivated polio vaccine) 30 days prior to the diphtheria and tetanus toxoids, and acellular pertussis vaccine.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Daptacel (diphtheria and tetanus toxoids, and acellular pertussis vaccine) [prescribing information]. Swiftwater, PA: Sanofi Pasteur Inc; September 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10782":"<p><b>Title</b> EPINEPHrine (Systemic) / Benperidol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Benperidol may diminish the therapeutic effect of EPINEPHrine (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased epinephrine effectiveness if combined with benperidol.</p> \n<p><b>Discussion</b> Benperidol product labeling states that benperidol may antagonize the effects of epinephrine.<sup>1</sup> <br><br>The reason for this label warning is unclear, but other antipsychotic agents with alpha-adrenergic blocking actions (ie, promethazine, chlorpromazine) are thought to oppose the vasoconstrictive actions of epinephrine without opposing beta-stimulating effects, leading to net peripheral vasodilation and/or tachycardia.<sup>1</sup> The effects of benperidol on alpha-adrenergic receptors are unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Anquil (benperidol) [summary of product characteristics]. Galashiels, UK: Archimedes Pharma UK Limited; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10783":"<p><b>Title</b> Benperidol / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Benperidol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased benperidol effects if combined with strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Benperidol product labeling states that concomitant use of benperidol with strong CYP3A4 inducers may increase benperidol metabolism and lead to decreased benperidol efficacy.<sup>1</sup> However, the enzymes involved in benperidol metabolism have not been identified, so the effect of coadministration with strong CYP3A4 inducers is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Anquil (benperidol) [summary of product characteristics]. Galashiels, UK: Archimedes Pharma UK Limited; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10784":"<p><b>Title</b> Benperidol / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Benperidol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased benperidol effects/toxicities if combined with strong CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Benperidol product labeling states that concomitant use of benperidol with strong CYP3A4 inhibitors may decrease benperidol metabolism and lead to increased benperidol effects/toxicities.<sup>1</sup> However, the enzymes involved in benperidol metabolism have not been identified, so the effect of coadministration with strong CYP3A4 inhibitors is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Anquil (benperidol) [summary of product characteristics]. Galashiels, UK: Archimedes Pharma UK Limited; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10785":"<p><b>Title</b> Blood Pressure Lowering Agents / Benperidol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Benperidol may enhance the hypotensive effect of Blood Pressure Lowering Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased hypotensive effects if benperidol is combined with blood pressure lowering agents.</p>\n<div>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Benperidol prescribing information states that concomitant use of benperidol with blood pressure lowering agents may increase the risk of hypotension.<sup>1</sup> Dose-related hypotension is uncommon with benperidol, but can occur, particularly in elderly patients who are more susceptible to the sedative and hypotensive effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Anquil (benperidol) [summary of product characteristics]. Galashiels, UK: Archimedes Pharma UK Limited; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10786":"<p><b>Title</b> Benperidol / Memantine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Memantine may diminish the therapeutic effect of Benperidol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased benperidol effects if combined with memantine.</p> \n<p><b>Discussion</b> Benperidol product labeling states that the effects of benperidol may be reduced if combined with memantine.<sup>1</sup> The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Anquil (benperidol) [summary of product characteristics]. Galashiels, UK: Archimedes Pharma UK Limited; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10787":"<p><b>Title</b> Urea Cycle Disorder Agents / Benperidol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Benperidol may diminish the therapeutic effect of Urea Cycle Disorder Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Enhanced plasma ammonia monitoring may be required to guide dose titration of phenylbutyrate products following benperidol initiation or dose modification.</p>\n<div>\n <p><b>Urea Cycle Disorder Agents Interacting Members</b> Glycerol Phenylbutyrate, Sodium Phenylbutyrate</p>\n</div> \n<p><b>Discussion</b> According to US prescribing information for sodium phenylbutyrate and glycerol phenylbutyrate products, caution may be warranted with coadministration of agents such as valproate or haloperidol that have been associated with hyperammonemia.<sup>1,2</sup> Benperidol product labeling also cautions that a similar interaction may occur with benperidol.<sup>3</sup> Enhanced monitoring of ammonia concentrations may be necessary to guide appropriate phenylbutyrate dose adjustment following initiation or dose modification of these drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ravicti (glycerol phenylbutyrate) [prescribing information]. South San Francisco, CA: Hyperion Therapeutics Inc; February 2013.</p>\n<p>2. Buphenyl (sodium phenylbutyrate) [prescribing information]. Scottsdale, AZ: Ucyclyd Pharma Inc; February 2009.</p>\n<p>3. Anquil (benperidol) [summary of product characteristics]. Galashiels, UK: Archimedes Pharma UK Limited; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10788":"<p><b>Title</b> CloZAPine / CYP1A2 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP1A2 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients receiving moderate CYP1A2 inhibitors with clozapine for evidence of clozapine toxicity. Clozapine dose reduction may be needed. Monitor for diminished clozapine effectiveness and need for dose escalation in patients who have recently discontinued moderate CYP1A2 inhibitors.</p>\n<div>\n <p><b>CYP1A2 Inhibitors (Moderate) Interacting Members</b> Ciprofloxacin (Systemic), Deferasirox, Methoxsalen (Systemic), Mexiletine, Stiripentol, Thiabendazole, Vemurafenib</p>\n</div> \n<p><b>Discussion</b> Clozapine US prescribing information states that patients receiving moderate or weak CYP1A2 inhibitors should be monitored for clozapine adverse reactions and the need for reduced clozapine doses.<sup>1</sup> The suspected primary mechanism of this interaction is inhibition of CYP1A2-mediated clozapine metabolism. Weak or moderate inhibition of CYP1A2 is expected to increase clozapine exposure to a lesser extent than strong CYP1A2 inhibitors (eg, ciprofloxacin, fluvoxamine), which have been associated in some investigations with 2-fold or greater increases in clozapine serum concentrations and AUC.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Clozaril (clozapine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; September 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10789":"<p><b>Title</b> CloZAPine / CYP1A2 Inhibitors (Weak)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients receiving weak CYP1A2 inhibitors with clozapine for evidence of clozapine toxicity. Clozapine dose reduction may be needed. Monitor for diminished clozapine effectiveness and the need for dose escalation in patients who have recently discontinued weak CYP1A2 inhibitors.</p>\n<div>\n <p><b>CYP1A2 Inhibitors (Weak) Interacting Members</b> Acyclovir (Systemic), Caffeine, Cimetidine, Disulfiram, Estradiol (Systemic), Estradiol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Ethinyl Estradiol, Glecaprevir and Pibrentasvir, Interferon Alfa-2b, Kola Nut, Mestranol, Obeticholic Acid, Pefloxacin, Peginterferon Alfa-2a, Peginterferon Alfa-2b, Pipemidic Acid, Propafenone, Propranolol, Simeprevir, Ticlopidine, ValACYclovir, Verapamil, Zileuton</p>\n</div> \n<p><b>Discussion</b> Clozapine US prescribing information states that patients receiving moderate or weak CYP1A2 inhibitors should be monitored for clozapine adverse reactions and the need for reduced clozapine doses.<sup>1</sup> The suspected primary mechanism of this interaction is inhibition of CYP1A2-mediated clozapine metabolism. Weak or moderate inhibition of CYP1A2 is expected to increase clozapine exposure to a lesser extent than strong CYP1A2 inhibitors (eg, ciprofloxacin, fluvoxamine), which have been associated in some investigations with 2-fold or greater increases in clozapine serum concentrations and AUC.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Clozaril (clozapine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; September 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10790":"<p><b>Title</b> CloZAPine / CYP2D6 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may increase the serum concentration of CloZAPine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients receiving strong CYP2D6 inhibitorswith clozapine for evidence of clozapine toxicity. Clozapine dose reduction may be needed. Monitor for diminished clozapine effectiveness and need for dose escalation in patients who have recently discontinued strong CYP2D6 inhibitors.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> Clozapine US prescribing information states that patients receiving CYP2D6 inhibitors should be monitored for clozapine adverse reactions and the need for reduced clozapine doses.<sup>1</sup><br><br>Several reports describe increased clozapine concentrations (less than 2 fold) and/or reduced clozapine dose requirements in patients receiving the CYP2D6 inhibitors fluoxetine or paroxetine, with some reports also describing increases in clozapine effects.<sup>1,2,3,4,5,6,7,8,9</sup> Some case reports also describe serious toxicities during concomitant use of these agents.<sup>10,11</sup> However, at least 3 clinical studies have concluded that paroxetine has no significant impact on clozapine concentrations or effects.<sup>11,12,13</sup><br><br>The suspected primary mechanism of interaction between these agents is inhibition of CYP2D6-mediated clozapine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Clozaril (clozapine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2015.</p>\n<p>2. Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, Flood JG. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. <i>Am J Psychiatry</i>. 1996;153(6):820-822. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8633698\">[PubMed 8633698]</a></p>\n<p>3. Centorrino F, Baldessarini RJ, Kando J, et al. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. <i>Am J Psychiatry</i>. 1994;151(1):123-125. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8267110\">[PubMed 8267110]</a></p>\n<p>4. Cassady SL, Thaker GK. Addition of fluoxetine to clozapine [published correction appears in Am J Psychiatry. 1992;149(11):1622] . <i>Am J Psychiatry</i>. 1992;149(9):1274. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1503143\">[PubMed 1503143]</a></p>\n<p>5. Joos AA, Koenig F, Frank UG, Kaschka WP, Morike KE, Ewald R. Dose-dependent pharmacokinetic interaction of clozapine and paroxetine in an extensive metabolizer. <i>Pharmacopsychiatry</i>. 1997;30(6):266-270. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9442550\">[PubMed 9442550]</a></p>\n<p>6. Chong SI, Tan CH, Lee HS. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports. <i>J Clin Psychopharmacol</i>. 1997;17(1):68-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9004072\">[PubMed 9004072]</a></p>\n<p>7. Spina E, Avenoso A, Facciola G, et al. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. <i>Int Clin Psychopharmacol</i>. 1998;13(3):141-145. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9690983\">[PubMed 9690983]</a></p>\n<p>8. Spina E, Avenoso A, Salemi M, et al. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. <i>Pharmacopsychiatry</i>. 2000;33(6):213-217. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11147928\">[PubMed 11147928]</a></p>\n<p>9. Diaz FJ, Santoro V, Spina E, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. <i>Pharmacopsychiatry</i>. 2008;41(3):81-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18484549\">[PubMed 18484549]</a></p>\n<p>10. Ferslew KE, Hagardorn AN, Harlan GC, McCormick WF. A fatal drug interaction between clozapine and fluoxetine. <i>J Forensic Sci</i>. 1998;43(5):1082-1085. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9729831\">[PubMed 9729831]</a></p>\n<p>11. Gambassi G, Capurso S, Tarsitani P, Liperoti R, Bernabei R. Fatal neuroleptic malignant syndrome in a previously long-term user of clozapine following its reintroduction in combination with paroxetine. <i>Aging Clin Exp Res</i>. 2006;18(3):266-270. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16804375\">[PubMed 16804375]</a></p>\n<p>12. Anghelescu I, Szegedi A, Schlegel S, Weigmann H, Hiemke C, Wetzel H. Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial. <i>Eur Neuropsychopharmacol</i>. 1998;8(4):315-320. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9928923\">[PubMed 9928923]</a></p>\n<p>13. Wetzel H, Anghelescu I, Szegedi A, et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. <i>J Clin Psychopharmacol</i>. 1998;18(1):2-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9472836\">[PubMed 9472836]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10791":"<p><b>Title</b> CloZAPine / CYP2D6 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients receiving moderate CYP2D6 inhibitors in combination with clozapine for evidence of clozapine toxicity. Clozapine dose reduction may be needed. Similarly, monitor for diminished clozapine effectiveness and need for dose escalation in patients who have recently discontinued moderate CYP2D6 inhibitors.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Moderate) Interacting Members</b> Abiraterone Acetate, Asunaprevir, BuPROPion, Cinacalcet, Darifenacin, Darunavir, DULoxetine, Lorcaserin, Mirabegron, Perhexiline, Rolapitant, Terbinafine (Systemic), Thioridazine</p>\n</div> \n<p><b>Discussion</b> Clozapine US prescribing information states that patients receiving CYP2D6 inhibitors should be monitored for clozapine adverse reactions and the need for reduced clozapine doses.<sup>1</sup><br><br>Several reports describe increased clozapine concentrations (less than 2 fold) and/or reduced clozapine dose requirements in patients receiving the CYP2D6 inhibitors fluoxetine or paroxetine, with some reports also describing increases in clozapine effects.<sup>1,2,3,4,5,6,7,8,9</sup> Some case reports also describe serious toxicities during concomitant use of these agents.<sup>10,11</sup> In contrast to these reports, at least 3 clinical studies have concluded that paroxetine has no significant impact on clozapine concentrations or effects.<sup>11,12,13</sup><br><br>The suspected primary mechanism of interaction between these agents is inhibition of CYP2D6-mediated clozapine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Clozaril (clozapine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2015.</p>\n<p>2. Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, Flood JG. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. <i>Am J Psychiatry</i>. 1996;153(6):820-822. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8633698\">[PubMed 8633698]</a></p>\n<p>3. Centorrino F, Baldessarini RJ, Kando J, et al. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. <i>Am J Psychiatry</i>. 1994;151(1):123-125. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8267110\">[PubMed 8267110]</a></p>\n<p>4. Cassady SL, Thaker GK. Addition of fluoxetine to clozapine. <i>Am J Psychiatry</i>. 1992;149(9):1274. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1503143\">[PubMed 1503143]</a></p>\n<p>5. Joos AA, Koenig F, Frank UG, Kaschka WP, Morike KE, Ewald R. Dose-dependent pharmacokinetic interaction of clozapine and paroxetine in an extensive metabolizer. <i>Pharmacopsychiatry</i>. 1997;30(6):266-270. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9442550\">[PubMed 9442550]</a></p>\n<p>6. Chong SI, Tan CH, Lee HS. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports. <i>J Clin Psychopharmacol</i>. 1997;17(1):68-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9004072\">[PubMed 9004072]</a></p>\n<p>7. Spina E, Avenoso A, Facciola G, et al. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. <i>Int Clin Psychopharmacol</i>. 1998;13(3):141-145. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9690983\">[PubMed 9690983]</a></p>\n<p>8. Spina E, Avenoso A, Salemi M, et al. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. <i>Pharmacopsychiatry</i>. 2000;33(6):213-217. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11147928\">[PubMed 11147928]</a></p>\n<p>9. Diaz FJ, Santoro V, Spina E, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. <i>Pharmacopsychiatry</i>. 2008;41(3):81-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18484549\">[PubMed 18484549]</a></p>\n<p>10. Ferslew KE, Hagardorn AN, Harlan GC, McCormick WF. A fatal drug interaction between clozapine and fluoxetine. <i>J Forensic Sci</i>. 1998;43(5):1082-1085. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9729831\">[PubMed 9729831]</a></p>\n<p>11. Gambassi G, Capurso S, Tarsitani P, Liperoti R, Bernabei R. Fatal neuroleptic malignant syndrome in a previously long-term user of clozapine following its reintroduction in combination with paroxetine. <i>Aging Clin Exp Res</i>. 2006;18(3):266-270. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16804375\">[PubMed 16804375]</a></p>\n<p>12. Anghelescu I, Szegedi A, Schlegel S, Weigmann H, Hiemke C, Wetzel H. Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial. <i>Eur Neuropsychopharmacol</i>. 1998;8(4):315-320. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9928923\">[PubMed 9928923]</a></p>\n<p>13. Wetzel H, Anghelescu I, Szegedi A, et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. <i>J Clin Psychopharmacol</i>. 1998;18(1):2-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9472836\">[PubMed 9472836]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10792":"<p><b>Title</b> CloZAPine / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of CloZAPine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients receiving moderate CYP3A4 inducers with clozapine for evidence of diminished clozapine effectiveness. Clozapine dose escalation may be needed. Monitor for increased clozapine effects and need for dose reduction in patients who have recently discontinued moderate CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> Clozapine US prescribing information states that patients receiving weak or moderate CYP3A4 inducers should be monitored for diminished clozapine effects and the need for increased clozapine doses.<sup>1</sup><br><br>No clinical data characterizing the magnitude of interaction between moderate or weak CYP3A4 inducers and clozapine are available. Case reports describe reduced clozapine concentrations (47 to 50% reductions in concentration or concentration/dose ratio) and worsening of psychiatric symptoms with the strong CYP3A4 inducer carbamazepine and with St. John's wort.<sup>2,3,4</sup> Another report describes a significant increase in clozapine concentrations and adverse effects following a change from carbamazepine to oxcarbazepine, an agent associated with much weaker CYP3A4 induction.<sup>5</sup> Reports also describe reduced clozapine concentrations and effectiveness with concurrent use of the strong inducers phenytoin and rifampin.<sup>6,7,8</sup> <br><br>Some reports suggest that concurrent use of clozapine with enzyme inducers such as carbamazepine may also be associated with a greater risk for clozapine adverse effects,<sup>9,10</sup> which may be related to the relatively greater concentration of metabolites such as norclozapine.<sup>11</sup> The clinical significance of any such shift in metabolite concentrations is unclear.<br><br>The suspected primary mechanism of this interaction is induction of CYP3A4-mediated clozapine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Clozaril (clozapine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; September 2015.</p>\n<p>2. Van Strater AC, Bogers JP. Interaction of St Johns wort (Hypericum perforatum) with clozapine. <i>Int Clin Psychopharmacol</i>. 2012;27(2):121-124. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22113252\">[PubMed 22113252]</a></p>\n<p>3. Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. <i>Pharmacopsychiatry</i>. 1995;28(1):26-28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7746842\">[PubMed 7746842]</a></p>\n<p>4. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. <i>Ther Drug Monit</i>. 1994;16(4):368-374. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7974626\">[PubMed 7974626]</a></p>\n<p>5. Raitasuo V, Lehtovaara R, Huttunen MO. Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. A case report. <i>Psychopharmacology (Berl)</i>. 1994;116(1):115-116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7862923\">[PubMed 7862923]</a></p>\n<p>6. Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. <i>J Clin Psychiatry</i>. 1991;52(1):23-25. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1988414\">[PubMed 1988414]</a></p>\n<p>7. Peritogiannis V, Pappas D, Antoniou K, Hyphantis T, Mavreas V. Clozapine-rifampicin interaction in a patient with pulmonary tuberculosis. <i>Gen Hosp Psychiatry</i>. 2007;29(3):281-282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17484952\">[PubMed 17484952]</a></p>\n<p>8. Joos AA, Frank UG, Kaschka WP. Pharmacokinetic interaction of clozapine and rifampicin in a forensic patient with an atypical mycobacterial infection. <i>J Clin Psychopharmacol</i>. 1998;18(1):83-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9472849\">[PubMed 9472849]</a></p>\n<p>9. Muller T, Becker T, Fritze J. Neuroleptic malignant syndrome after clozapine plus carbamazepine. <i>Lancet</i>. 1988;2(8626-8627):1500. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2904624\">[PubMed 2904624]</a></p>\n<p>10. Junghan U, Albers M, Woggon B. Increased risk of hematological side-effects in psychiatric patients treated with clozapine and carbamazepine? <i>Pharmacopsychiatry</i>. 1993;26(6):262. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8127933\">[PubMed 8127933]</a></p>\n<p>11. Langbehn DR, Alexander B. Increased risk of side-effects in psychiatric patients treated with clozapine and carbamazepine: a reanalysis. <i>Pharmacopsychiatry</i>. 2000;33(5):196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11071023\">[PubMed 11071023]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10793":"<p><b>Title</b> CloZAPine / CYP3A4 Inducers (Weak)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients receiving weak CYP3A4 inducers with clozapine for evidence of diminished clozapine effectiveness. Clozapine dose escalation may be needed. Monitor for increased clozapine effects and need for dose reduction in patients who have recently discontinued weak CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Weak) Interacting Members</b> Armodafinil, Artemether, Asunaprevir, CloBAZam, Desvenlafaxine, Dexamethasone (Systemic), Echinacea, Ginkgo Biloba, Glycerol Phenylbutyrate, Lesinurad, Licorice, Nevirapine, OXcarbazepine, Rifabutin, Rufinamide, Telotristat Ethyl, Vemurafenib</p>\n</div> \n<p><b>Discussion</b> Clozapine US prescribing information states that patients receiving weak or moderate CYP3A4 inducers should be monitored for diminished clozapine effects and the need for increased clozapine doses.<sup>1</sup><br><br>No clinical data characterizing the magnitude of interaction between moderate or weak CYP3A4 inducers and clozapine are available. Case reports describe reduced clozapine concentrations (47 to 50% reductions in concentration or concentration/dose ratio) and worsening of psychiatric symptoms with the strong CYP3A4 inducer carbamazepine and with St. John's wort.<sup>2,3,4</sup> Another report describes a significant increase in clozapine concentrations and adverse effects following a change from carbamazepine to oxcarbazepine, an agent associated with much weaker CYP3A4 induction.<sup>5</sup> Reports also describe reduced clozapine concentrations and effectiveness with concurrent use of the strong inducers phenytoin and rifampin.<sup>6,7,8</sup> <br><br>Some reports suggest that concurrent use of clozapine with enzyme inducers such as carbamazepine may also be associated with a greater risk for clozapine adverse effects,<sup>9,10</sup> which may be related to the relatively greater concentration of metabolites such as norclozapine.<sup>11</sup> The clinical significance of any such shift in metabolite concentrations is unclear.<br><br>The suspected primary mechanism of this interaction is induction of CYP3A4-mediated clozapine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Clozaril (clozapine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; September 2015.</p>\n<p>2. Van Strater AC, Bogers JP. Interaction of St Johns wort (Hypericum perforatum) with clozapine. <i>Int Clin Psychopharmacol</i>. 2012;27(2):121-124. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22113252\">[PubMed 22113252]</a></p>\n<p>3. Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. <i>Pharmacopsychiatry</i>. 1995;28(1):26-28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7746842\">[PubMed 7746842]</a></p>\n<p>4. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. <i>Ther Drug Monit</i>. 1994;16(4):368-374. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7974626\">[PubMed 7974626]</a></p>\n<p>5. Raitasuo V, Lehtovaara R, Huttunen MO. Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. A case report. <i>Psychopharmacology (Berl)</i>. 1994;116(1):115-116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7862923\">[PubMed 7862923]</a></p>\n<p>6. Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. <i>J Clin Psychiatry</i>. 1991;52(1):23-25. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1988414\">[PubMed 1988414]</a></p>\n<p>7. Peritogiannis V, Pappas D, Antoniou K, Hyphantis T, Mavreas V. Clozapine-rifampicin interaction in a patient with pulmonary tuberculosis. <i>Gen Hosp Psychiatry</i>. 2007;29(3):281-282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17484952\">[PubMed 17484952]</a></p>\n<p>8. Joos AA, Frank UG, Kaschka WP. Pharmacokinetic interaction of clozapine and rifampicin in a forensic patient with an atypical mycobacterial infection. <i>J Clin Psychopharmacol</i>. 1998;18(1):83-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9472849\">[PubMed 9472849]</a></p>\n<p>9. Muller T, Becker T, Fritze J. Neuroleptic malignant syndrome after clozapine plus carbamazepine. <i>Lancet</i>. 1988;2(8626-8627):1500. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2904624\">[PubMed 2904624]</a></p>\n<p>10. Junghan U, Albers M, Woggon B. Increased risk of hematological side-effects in psychiatric patients treated with clozapine and carbamazepine? <i>Pharmacopsychiatry</i>. 1993;26(6):262. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8127933\">[PubMed 8127933]</a></p>\n<p>11. Langbehn DR, Alexander B. Increased risk of side-effects in psychiatric patients treated with clozapine and carbamazepine: a reanalysis. <i>Pharmacopsychiatry</i>. 2000;33(5):196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11071023\">[PubMed 11071023]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10797":"<p><b>Title</b> Sirolimus / Acitretin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Acitretin may increase the serum concentration of Sirolimus. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for increased sirolimus levels and toxicities if combined with acitretin.</p> \n<p><b>Discussion</b> One case report describes a 47-year-old renal transplant recipient treated with sirolimus (trough concentrations 5.2 ng/mL) who experienced a 5-fold increase in sirolimus trough concentrations 4 weeks after initiation of acitretin (10 mg daily) for the treatment of multiple cutaneous squamous cell carcinomas.<sup>1</sup> Acitretin was discontinued and sirolimus concentrations returned to baseline 2 months later.<sup>1</sup><br><br>The mechanism of this potential interaction is unknown. Sirolimus is primarily metabolized and transported by CYP3A4 and P-glycoprotein (P-gp), but there are no data to suggest that acitretin can inhibit CYP3A4, and evidence that acitretin can inhibit P-gp is very limited.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rossi AM, Hibler BP, Johnson-Jahangir H. Serum sirolimus level elevation induced by acitretin: report of a novel drug-drug interaction. <i>J Drugs Dermatol</i>. 2015;14(7):747-749. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26151793\">[PubMed 26151793]</a></p>\n<p>2. Chang C, Bahadduri PM, Polli JE, Swaan PW, Ekins S. Rapid identification of P-glycoprotein substrates and inhibitors. <i>Drug Metab Dispos</i>. 2006;34(12):1976-1984. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16997908\">[PubMed 16997908]</a></p>\n<p>3. Soriatane (acitretin) [prescribing information]. Research Triangle Park, NC: Stiefel Laboratories Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10798":"<p><b>Title</b> Erlotinib / Teriflunomide</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Teriflunomide may decrease the serum concentration of Erlotinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of erlotinib and teriflunomide if possible. If concomitant use is unavoidable, increase the erlotinib dose by 50 mg increments at 2-week intervals to a maximum of 300 mg.</p> \n<p><b>Discussion</b> In a study of healthy volunteers described in the erlotinib prescribing information, current cigarette smokers (tobacco is a moderate CYP1A2 inducer) had an erlotinib AUC that was 64% lower than that of former/never smokers.<sup>1</sup> In a study of patients with non-small cell lung cancer, current smokers achieved erlotinib steady-state trough plasma concentrations that were approximately 2-fold less than that of former smokers or patients who had never smoked.<sup>1</sup><br><br>Erlotinib prescribing information states that erlotinib and moderate CYP1A2 inducers (ie, teriflunomide) should be avoided if possible.<sup>1</sup> If concomitant use is unavoidable, increase the erlotinib dose by 50 mg increments at 2-week intervals to a maximum of 300 mg.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tarceva (erlotinib) [prescribing information]. South San Francisco, CA: Genentech USA Inc; September 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10799":"<p><b>Title</b> Erlotinib / Leflunomide</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Leflunomide may decrease the serum concentration of Erlotinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of erlotinib and leflunomide if possible. If concomitant use is unavoidable, increase the erlotinib dose by 50 mg increments at 2-week intervals to a maximum of 300 mg.</p> \n<p><b>Discussion</b> In a study of healthy volunteers described in the erlotinib prescribing information, current cigarette smokers (tobacco is a moderate CYP1A2 inducer) had an erlotinib AUC that was 64% lower than that of former/never smokers.<sup>1</sup> In a study of patients with non-small cell lung cancer, current smokers achieved erlotinib steady-state trough plasma concentrations that were approximately 2-fold less than that of former smokers or patients who had never smoked.<sup>1</sup><br><br>Erlotinib prescribing information states that erlotinib and moderate CYP1A2 inducers (ie, leflunomide) should be avoided if possible.<sup>1</sup> If concomitant use is unavoidable, increase the erlotinib dose by 50 mg increments at 2-week intervals to a maximum of 300 mg.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tarceva (erlotinib) [prescribing information]. South San Francisco, CA: Genentech USA Inc; September 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}